---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Product information and disease description. Covers Product description and Place of product in therapy. 367 evidence topics quoted from 136 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: regulatory status and development history

- Approval: the FDA approved Lembaz (adrabetadex) injection under NDA 220996 on November 17, 2026, as a “Type 1 - New Molecular Entity” with priority review and orphan status. The FDA describes it as the first treatment shown to help people with a “severe form of Niemann-Pick disease type C (NPC) live longer”. Beren Therapeutics states that LEMBAZ will be available at commercial treatment sites nationwide in early December.
- Application and review: Beren Therapeutics, through its subsidiary Mandos LLC, submitted the NDA on December 17, 2025 for the treatment of patients with infantile-onset NPC. The application was based on an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives. The FDA granted priority review and assigned a PDUFA target action date of August 17, 2026. Beren's March 18, 2026 response to an FDA information request was classified as a major amendment, which extended the goal date by three months to November 17, 2026. The application was not referred to an FDA advisory committee.
- Designations: the FDA designated 2-hydroxypropyl-B-cyclodextrin an orphan drug for the treatment of Niemann Pick disease, type C on 02/18/2013, with Mandos LLC as the sponsor. The European Commission granted orphan designation EU/3/13/1124 on 26 April 2013 to the International Niemann-Pick Disease Alliance; sponsorship was transferred to Vtesse Europe Limited in February 2015, Mallinckrodt Pharmaceuticals Ireland Limited in September 2018, Rapport Global Strategic Services Ireland Limited in December 2021, and Eliquent Life Sciences Limited in August 2024. Adrabetadex also holds rare pediatric disease designation. The FDA granted Vtesse Breakthrough Therapy designation for VTS-270 in Niemann-Pick Type C1 disease on January 6, 2016 and later rescinded it based on data from a 12-month phase 2b/3 trial; a second Breakthrough Therapy designation, for infantile-onset NPC, was announced on December 9, 2025 and was informed by an externally controlled survival analysis.
- Priority review voucher and patents: the FDA granted a rare pediatric disease priority review voucher (PRV NDA 220996) with the approval, which may be transferred, including by sale. Earlier agreements refer to shares of voucher proceeds: Sucampo agreed in 2017 to pay Vtesse shareholders a share of net proceeds from monetization of the voucher, and the Mallinckrodt plan of reorganization refers to the Debtors' 63% retained ownership interest in the voucher. Beren states that its intellectual property estate provides patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates, and that it holds more than 30 issued U.S. patents.
- Development history: researchers at the NIH National Center for Advancing Translational Sciences and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, in collaboration with Vtesse, developed VTS-270. After its launch in January 2015, Vtesse fully enrolled the registrational study at 20 clinical trial sites. Sucampo acquired Vtesse on April 3, 2017 for upfront consideration of $200 million plus contingent royalties, and Mallinckrodt acquired Sucampo, and with it VTS-270, in February 2018. At a Type A meeting in August 2018, the FDA indicated that approvability would be based on the totality of data; in November 2018 Mallinckrodt announced that the registration trial did not show a statistically significant separation from placebo. In the three months ended December 27, 2019, Mallinckrodt recognized a full impairment of $274.5 million on the VTS-270 asset, “primarily driven by continued regulatory challenges”, and trial NCT03643562 ended after the sponsor determined that the benefit-risk profile of adrabetadex was not favorable. Mandos acquired the program from Mallinckrodt in 2021, held an introductory call and a Type C meeting with the FDA, and completed new analyses of adrabetadex before the NDA submission.
- Earlier timelines: in April 2017 Sucampo expected pivotal trial results in mid-2018 and a launch beginning in 2019, and a YODA Project data request projected an NDA submission by December 2023 toward accelerated approval.

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf); [Drugs@FDA NDA 220996](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220996); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/); [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/); [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/); [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/); [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/); [FDA Orphan Drug Designations and Approvals (2013)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=386412); [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124); [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/); [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease); [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm); [Mallinckrodt plan of reorganization exhibit (2021)](https://www.sec.gov/Archives/edgar/data/1567892/000119312521264916/d41435dex993.htm); [Beren Therapeutics patent estate press release (2026)](https://www.berentx.com/news/beren-therapeutics-expands-cyclodextrin-intellectual-property-estate-with-eight-new-u-s-issued-patents/); [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm); [Mallinckrodt Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1567892/000156789220000005/mnk10-k122719.htm); [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562); [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/); [Beren Therapeutics October 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-october-2024/); [Beren Therapeutics October 2025 community update (2025)](https://www.berentx.com/news/npc-community-update-october-2025/); [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Approved; NDA submitted December 2025 and approved November 2026

> “Please refer to your new drug application (NDA) received December 17, 2025, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Lembaz (adrabetadex) injection.”
> “We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
| --- | --- | --- | --- | --- |
| “11/17/2026” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |

Source: [Drugs@FDA NDA 220996](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220996)

> “We are pleased to share that on December 17, 2025, Beren Therapeutics P.B.C.®, through its subsidiary Mandos LLC®, submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for adrabetadex.”
> “This application seeks approval for the treatment of patients with infantile-onset Niemann-Pick disease type C (NPC).”

Source: [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)

<a id="topic-2.1.1-3"></a>

##### Launch: Approved November 2026, with commercial availability expected in early December 2026

> “LEMBAZ will be available at commercial sites nationwide in early December.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

> “I am so pleased to finally share with you all that today, the U.S. Food and Drug Administration (FDA) approved LEMBAZ™ (adrabetadex).”
> “LEMBAZ will be available at commercial treatment sites nationwide in early December.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

<a id="topic-2.1.1-4"></a>

##### FDA approval in November 2026

> “The U.S. Food and Drug Administration today approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “Initial U.S. Approval: 2026”
> “Revised: 11/2026”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.1-5"></a>

##### Review timeline: major amendment and three-month extension of the goal date

> “We acknowledge receipt of your major amendment dated March 18, 2026, which extended the goal date by three months.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

> “The new Prescription Drug User Fee Act (PDUFA) target action date is November 17, 2026.”
> “The extension follows Beren’s March 18, 2026 response to an FDA information request that included updates and clarifications to existing data and supporting documentation.”
> “The FDA classified the response as a Major Amendment to the NDA, which under FDA regulations extends the review period by three months.”

Source: [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/)

<a id="topic-2.1.1-6"></a>

##### Basis of the application: externally controlled survival analysis with confirmatory evidence

> “The application was based on data supporting a finding of improved survival in an externally controlled survival analysis, biomarker and nonclinical confirmatory evidence, and patient experience narratives.”

Source: [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/)

> “(VTS-270) in 2021, Mandos has worked closely with the FDA to define the regulatory path supporting this submission, including the design and implementation of an externally-controlled survival analysis.”

Source: [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)

<a id="topic-2.1.1-7"></a>

##### Expedited programs: priority review

> “Priority Review was requested on the basis that the application meets the qualifying criteria”

Source: [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/)

> “The NDA for adrabetadex was granted Priority Review by the FDA, and adrabetadex previously received Orphan Drug Designation and Breakthrough Therapy Designation.”

Source: [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/)

<a id="topic-2.1.1-8"></a>

##### Advisory committee

> “Your application for Lembaz was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.1.1-9"></a>

##### Breakthrough Therapy designation for infantile-onset disease, December 2025

> “THOUSAND OAKS, Calif.– December 9, 2025 – Beren Therapeutics P.B.C.®, a Public Benefit Corporation and parent company of Mandos LLC®, today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational drug for infantile-onset Niemann-Pick disease type C (NPC).”
> “The FDA decision was informed by an externally controlled survival analysis that showed adrabetadex improves survival in individuals with infantile-onset NPC and was reviewed alongside supportive biomarker and nonclinical data.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

> “Lembaz received Breakthrough Therapy designation.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.1.1-10"></a>

##### Breakthrough Therapy designation of January 2016, later rescinded

> “GAITHERSBURG, Md., Jan. 6, 2016 /PRNewswire/ -- Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status.”
> “Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.”

Source: [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease)

> “Adrabetadex previously received BTD in 2016 under a prior sponsor, and the FDA rescinded the designation based on data from a 12-month Phase 2b/3 clinical trial.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

<a id="topic-2.1.1-11"></a>

##### Orphan drug designation in the United States, February 2013

| Field | Quoted record |
| --- | --- |
| Generic name | “2-hydroxypropyl-B-cyclodextrin” |
| Date designated | “02/18/2013” |
| Orphan designation | “Treatment of Niemann Pick disease, type C.” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Mandos LLC” |

Source: [FDA Orphan Drug Designations and Approvals (2013)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=386412)

<a id="topic-2.1.1-12"></a>

##### Orphan designation in the European Union, April 2013, and transfers of sponsorship

> “On 26 April 2013, orphan designation (EU/3/13/1124) was granted by the European Commission to International Niemann-Pick Disease Alliance (INPDA), the United Kingdom, for 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick disease, type C.”

Source: [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124)

| Date | Update |
| --- | --- |
| “August 2024” | “The sponsorship was transferred to Eliquent Life Sciences Limited.” |
| “December 2021” | “The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited.” |
| “September 2018” | “The sponsorship was transferred to Mallinckrodt Pharmaceuticals Ireland Limited.” |
| “February 2015” | “The sponsorship was transferred to Vtesse Europe Limited, United Kingdom.” |

Source: [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124)

<a id="topic-2.1.1-13"></a>

##### Rare pediatric disease designation

> “Adrabetadex also has Orphan Drug and Rare Pediatric Disease designations.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

<a id="topic-2.1.1-14"></a>

##### Rare pediatric disease priority review voucher granted at approval

> “We also inform you that you have been granted a rare pediatric disease priority review voucher, as provided under section 529 of the FD&C Act.”
> “This priority review voucher (PRV) has been assigned a tracking number, PRV NDA 220996.”
> “This PRV may be transferred, including by sale, by you to another sponsor of a human drug or biologic application.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

> “The company received a Priority Review Voucher upon this approval.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.1-15"></a>

##### Priority review voucher proceeds: interests retained by earlier owners

> “Sucampo has acquired Vtesse for an upfront consideration of $200 million, and has agreed to pay Vtesse shareholders contingent consideration based on mid-single digit to double-digit royalties on global net sales of the product based on increasing net sales levels, and a share of net proceeds that may be generated from the monetization of the  pediatric review voucher, which is expected to be granted in connection with the approval of the product in the U.S.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

> “All proceeds received upon disposition of the Debtors’ 63% retained ownership interest in the priority review voucher related to VTS-270.”

Source: [Mallinckrodt plan of reorganization exhibit (2021)](https://www.sec.gov/Archives/edgar/data/1567892/000119312521264916/d41435dex993.htm)

<a id="topic-2.1.1-16"></a>

##### Patent estate statements, August 2026

> “Global intellectual property estate includes issued patents and pending applications supporting adrabetadex and Beren’s broader cholesterol-trafficking pipeline with patent protection through 2046, excluding potential patent term extensions, patent term adjustments, and supplementary protection certificates.”
> “Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced that the U.S. Patent and Trademark Office has issued eight new U.S. patents related to Beren’s proprietary derivatized cyclodextrins, including adrabetadex, increasing Beren’s U.S. patent portfolio to more than 30 issued patents.”

Source: [Beren Therapeutics patent estate press release (2026)](https://www.berentx.com/news/beren-therapeutics-expands-cyclodextrin-intellectual-property-estate-with-eight-new-u-s-issued-patents/)

<a id="topic-2.1.1-17"></a>

##### Development history: origin at the National Institutes of Health and Vtesse

> “Researchers at the NIH's National Center for Advancing Translational Sciences (NCATS) and Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD), in close collaboration with Vtesse, patients and patient advocacy groups, developed VTS-270 as part of a project focused on finding treatments for NPC.”

Source: [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease)

> “Since its launch in January 2015, the Vtesse team has fully enrolled the registrational study of VTS-270 in NPC-1 at 20 clinical trial sites across the globe, providing broad access for study-eligible patients.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.1-18"></a>

##### Development history: acquisition of Vtesse by Sucampo, April 2017

> “ROCKVILLE, Md., and GAITHERSBURG, Md., April 03, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, and Vtesse Inc. (Vtesse), a privately-held rare disease company, today announced that Sucampo has acquired Vtesse for upfront consideration of $200 million.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.1-19"></a>

##### Development history: acquisition of Sucampo by Mallinckrodt, February 2018

> “In February 2018, the Company acquired Sucampo through the acquisition of all the outstanding common stock of Sucampo.”
> “Through this acquisition, the Company acquired VTS-270, a Phase 3 development product for Niemann-Pick Type C, a complicated, ultra-rare neurodegenerative disease that typically presents in childhood and is ultimately fatal.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

<a id="topic-2.1.1-20"></a>

##### Development history: phase 2b/3 result and FDA Type A meeting, 2018

> “In November 2018, we announced that the results of our recently completed registration trial for the product did not show a statistically significant separation from placebo.”
> “The FDA indicated at a Type A meeting in August 2018 that their view on the potential approvability will be based on the totality of data, not a single study or endpoint.”
> “We expect that a better understanding of the potential benefit of VTS-270 will emerge as we carefully consider the totality of data available and continue to work with the primary investigators and the FDA to determine the best path forward.”

Source: [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)

<a id="topic-2.1.1-21"></a>

##### Development history: full impairment of the VTS-270 asset, December 2019

> “During the three months ended December 27, 2019, we recognized a full impairment on our IPR&D asset related to VTS-270 of $274.5 million, primarily driven by continued regulatory challenges.”
> “The Company will continue to engage with the FDA and assess future opportunities for the development program.”

Source: [Mallinckrodt Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1567892/000156789220000005/mnk10-k122719.htm)

<a id="topic-2.1.1-22"></a>

##### Development history: termination of the open-label trial under the prior sponsor

> “Sponsor had determined that the benefit-risk profile of adrabetadex was not favorable and the clinical development program for adrabetadex was discontinued.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-2.1.1-23"></a>

##### Development history: transfer of the product from Mallinckrodt to Mandos, 2021

> “Beren, through its subsidiary Mandos, acquired the adrabetadex program from Mallinckrodt in 2021 and has worked closely with the FDA and NPC community to advance adrabetadex’s development and generate the data and analyses that supported the new BTD designation.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

> “We are pleased now to report that the final stage of transition from Mallinckrodt to Mandos is complete.”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-2.1.1-24"></a>

##### Development history: FDA meetings under Mandos, 2022 to 2024

> “We have completed our first meeting with the U.S. Food & Drug Administration (FDA).”
> “We recently had an FDA invited introductory call to discuss plans regarding the development of VTS-270 and introduce the Mandos team.”

Source: [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)

> “We are excited to announce the FDA has accepted our request for a Type C Meeting scheduled in October to discuss the direction of our adrabetadex program’s development.”

Source: [Beren Therapeutics September 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-september-2024/)

> “We are pleased to announce we had a productive Type C meeting with FDA on October 10.”

Source: [Beren Therapeutics October 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-october-2024/)

<a id="topic-2.1.1-25"></a>

##### PDUFA target action date of August 17, 2026, February 2026, superseded in May 2026

> “Accepted for priority review with Prescription Drug User Fee Act (PDUFA) action date of August 17, 2026”
> “The FDA assigned adrabetadex a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026.”

Source: [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)

<a id="topic-2.1.1-26"></a>

##### FDA decision timing, December 2025, superseded in February 2026

> “If accepted, we anticipate a regulatory decision regarding the NDA as early as Q3 2026.”

Source: [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)

<a id="topic-2.1.1-27"></a>

##### NDA submission timing, December 2025, superseded in December 2025

> “Beren plans to submit an NDA in the near future and expects adrabetadex to be eligible for Priority Review.”

Source: [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)

<a id="topic-2.1.1-28"></a>

##### NDA submission timing, October 2025, superseded in December 2025

> “Mandos Health has completed the new analyses of adrabetadex and is working towards a New Drug Application (NDA) submission.”

Source: [Beren Therapeutics October 2025 community update (2025)](https://www.berentx.com/news/npc-community-update-october-2025/)

<a id="topic-2.1.1-29"></a>

##### NDA submission timing and accelerated approval plan, 2021, superseded in December 2025

> “Once data is analyzed this would, depending on results, be used by Mandos to submit an NDA to FDA by December 2023 and then publish data while working with FDA on the response, such that publication would be expected in the second quarter of 2024.”
> “In this study, we will use information from the YODA NPC registry to add to the pool of control patients that can be used for case-control and natural history comparator studies to show a long-term effect of adrabetadex that will, if a sufficiently strong result, contribute to a registration application by Mandos for accelerated approval at FDA.”

Source: [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)

<a id="topic-2.1.1-30"></a>

##### Pivotal results timing, April 2017, superseded in November 2018

> “Results from the pivotal trial are expected in mid-2018.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.1-31"></a>

##### Launch timing, April 2017, superseded in November 2018

> “Product is expected to be launched and accretive to earnings beginning in 2019”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Generic name and brand name

> “LEMBAZ™ (adrabetadex) injection, for intrathecal use”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Drug name | Active ingredients | Strength | Dosage form/route | Marketing status |
| --- | --- | --- | --- | --- |
| “LEMBAZ” | “ADRABETADEX” | “900MG/4.5ML (200MG/ML)” | “INJECTION;SOLUTION” | “Prescription” |

Source: [Drugs@FDA NDA 220996](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220996)

<a id="topic-2.1.2.1-2"></a>

###### Development code and synonyms: VTS-270 and 2-hydroxypropyl-β-cyclodextrin

> “Adrabetadex (VTS-270) is a proprietary mixture of 2-hydroxypropyl-β-cyclodextrin isomers under investigation as a treatment for Niemann-Pick disease type C (NPC).”

Source: [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/)

> “VTS-270 is a well-characterized mixture of 2-hydroxypropyl-ß-cyclodextrins (HPßCD) with a specific compositional fingerprint that distinguishes it from other HPßCD mixtures.”

Source: [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)

<a id="topic-2.1.2.1-3"></a>

###### Manufacturer: Mandos LLC, a subsidiary of Beren Therapeutics

> “The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “Manufactured for: Mandos LLC, a subsidiary of Beren Therapeutics, PBC, Thousand Oaks, CA 91320”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Beren and its subsidiary Mandos LLC® have supported the NPC community by providing access to adrabetadex through an Expanded Access Program (EAP).”
> “Beren is a Public Benefit Corporation purpose-built to bring life-changing medicines to patients as quickly and responsibly as possible.”
> “Beren is headquartered in Thousand Oaks, Calif.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.1-4"></a>

###### Contract manufacturer

> “Manufactured by: Alcami, North Charleston, SC 29405”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.1-5"></a>

###### Therapeutic class: 2-hydroxypropyl-substituted beta cyclodextrin

> “Adrabetadex is a mixture of 2-hydroxypropyl-substituted beta cyclodextrin(s).”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Injection: strength and appearance

> “Injection: 900 mg/4.5 mL (200 mg/mL) of adrabetadex as a sterile, clear, colorless solution in a single-dose vial.”
> “LEMBAZ (adrabetadex) injection is supplied as a clear, colorless, preservative-free, sterile solution in a single-dose vial for intrathecal use.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Composition, inactive ingredients, and pH

> “Each 1 mL contains 200 mg of adrabetadex and inactive ingredients sodium chloride USP (2 mg) and Water for Injection USP.”
> “The pH is adjusted with hydrochloric acid and sodium hydroxide as needed. The pH is 6.0 to 8.0.”
> “The empirical formula is (C6H10O5)7(C3H6O)n, where n=4.1 to 4.8, and the average molecular weight is approximately 1,371 to 1,432 g/mol.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Package and national drug code

| Package | NDC number | Strength | Contents |
| --- | --- | --- | --- |
| Carton | “Carton: 87230-101-01” | “900 mg/4.5 mL” | “One single-dose vial in a carton” |
| Vial | “Vial: 87230-101-02” | “900 mg/4.5 mL” | “One single-dose vial in a carton” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Storage of the vial

> “Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30ºC (59°F to 86ºF) [see USP Controlled Room Temperature].”
> “Do not refrigerate. Do not freeze.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.2-5"></a>

###### Expiry dating period

> “Based on the stability data submitted to date, the expiry dating period for Lembaz (adrabetadex) injection shall be 36 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30ºC (59°F to 86ºF) [see USP Controlled Room Temperature].”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.1.2.2-6"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Summary: estimated monthly and annual cost

- Price basis: no wholesale acquisition cost (WAC) or list price for adrabetadex (Lembaz) had been published as of 18 November 2026, the date of the latest source; trade press reporting on the approval states that list pricing had not been announced.
- Dosing basis: per the prescribing information, adrabetadex is supplied as one 900 mg/4.5 mL single-dose vial per carton and is administered intrathecally every two weeks, with an age-based starting dose and upward titration to a weight-based maximum of 600 mg every two weeks (7 kg to less than 12 kg) or 900 mg every two weeks (12 kg or more). Every labeled dose is at or below 900 mg, so each administration uses one vial, assuming a whole vial per administration as the label gives no other basis. Every two weeks is 26 administrations, and therefore 26 vials, per year; the manufacturer's out-of-pocket program terms also cap support at 26 doses per year.
- Base case: not calculable, because no price has been published.
- Range: not calculable. With one vial per administration, annual drug cost will equal 26 times the vial price at every labeled dose and weight band, and monthly cost will equal annual cost divided by 12.
- Rationale for the range: the label varies the dose by age, body weight, audiology results, and dose reductions for ataxia or fatigue, but no labeled dose exceeds the content of one vial, so these sources of variation change the volume administered and leave the number of vials unchanged under the whole-vial assumption.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.

Source: [Pharmaphorum LEMBAZ approval report (2026)](https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [LEMBAZ Family Support terms and conditions (2026)](https://lembazrx.com/Co-Pay)

<a id="topic-2.1.2.3-2"></a>

###### Wholesale acquisition cost: not announced at approval

> “List pricing for the new product has not yet been announced.”

Source: [Pharmaphorum LEMBAZ approval report (2026)](https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### Drug information compendium classification

> “Classes: Neurologics, Other”

Source: [Medscape adrabetadex drug monograph (2026)](https://reference.medscape.com/drug/lembaz-adrabetadex-4000605)

> “Lembaz (adrabetadex) is a cyclodextrin-based therapeutic used to improve survival in infantile-onset Niemann-Pick disease type C.”

Source: [Drugs.com Lembaz FDA approval history (2026)](https://www.drugs.com/history/lembaz.html)

<a id="topic-2.1.2.4-3"></a>

###### ATC classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Approved indication

> “LEMBAZ™ is indicated to reduce the risk of mortality in adult and pediatric patients, who weigh 7 kg or greater, with Niemann-Pick disease type C (NPC) with neurological manifestations that started at less than 6 years of age.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “This NDA provides for the use of Lembaz (adrabetadex) injection to reduce the risk of mortality in adult and pediatric patients, who weigh 7 kg or greater, with Niemann-Pick disease type C (NPC) with neurological manifestations that started at less than 6 years of age.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.1.2.5-2"></a>

###### FDA and company descriptions of the approved population

> “Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile-onset NPC.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “LEMBAZ is approved for adults and children with NPC who had neurological manifestations that started before the age of 6.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.5-3"></a>

###### Patients outside the approved indication

> “I want to acknowledge that we know that not every family who needs treatment falls within today’s approved indication.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action: prescribing information

> “The mechanism(s) by which LEMBAZ exerts its clinical effects to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC with neurological manifestations that started at less than 6 years old has not been fully characterized.”
> “Adrabetadex has binding affinity for cholesterol and reduces lipid and ganglioside accumulation in the context of NPC by trafficking cholesterol out of the lysosome.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.1-2"></a>

###### Mechanism of action: manufacturer description at approval

> “LEMBAZ targets the cholesterol that builds up inside brain cells, which drives the neurological damage in NPC, by replacing the function of the NPC protein that is not working properly and helps move cholesterol to where the cell can use it.”
> “By re-establishing intracellular cholesterol trafficking, LEMBAZ addresses the underlying cause of NPC.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.6.1-3"></a>

###### Restoration of cholesterol trafficking in the central nervous system: company nonclinical studies

> “Adrabetadex re-establishes intracellular cholesterol trafficking within the CNS, addressing the central pathogenic defect in I-NPC and supporting its potential as foundational therapy.”
> “Adrabetadex is an investigational intrathecal therapy for infantile-onset NPC (I-NPC; neurological onset <6 years of age) and the only therapy designed to directly target accumulated intracellular cholesterol in the CNS, the central pathogenic driver of NPC.”

Source: [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Cyclodextrins as lipid-mobilizing agents

> “Recently, uncomplexed cyclodextrins have emerged as potent therapeutic compounds in their own right, based on their ability to sequester and mobilize cellular lipids.”
> “In particular, 2-hydroxypropyl-β-cyclodextrin (HPβCD) has garnered attention because of its cholesterol chelating properties, which appear to treat a rare neurodegenerative disorder and to promote atherosclerosis regression related to stroke and heart disease.”

Source: [Crumling et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5676048/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Cerebrospinal fluid biomarkers after 52 weeks of treatment

> “Following 52 weeks of treatment with LEMBAZ in patients with NPC, increased concentration of 24(S)-hydroxycholesterol and decreased concentrations of calbindin D and FABP3 in CSF were observed compared to baseline.”
> “The clinical significance of these biomarker changes has not been established.”
> “Plasma 24(S)-hydroxycholesterol and CSF calbindin D and FABP3 changed in an exposure-dependent manner across the LEMBAZ dosage range of 200 to 900 mg administered intrathecally every 2 weeks.”
> “The exposure-response relationship and the time course of the safety and effectiveness of LEMBAZ has not been fully characterized.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Target engagement in mouse and cat models: company nonclinical studies

> “Target engagement is directly linked to CNS exposure: adrabetadex dose-dependently reduces intracellular cholesterol across brain regions and increases 24(S)-OHC, consistent with enhanced efflux of accumulated cholesterol from the CNS.”
> “Adrabetadex treatment significantly increased brain 24(S)-OHC (p=0.0008), 72 hours after the second 0.8 mg ICV dose.”
> “24(S)-OHC production is proportional to both trafficking capability and the size of the accumulated cholesterol pool, indicating the need for repeated and frequent administrations to counteract the rate of ongoing cholesterol accumulation in I-NPC.”

Source: [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### Intracisternal administration in cats with Niemann-Pick disease type C1

> “In contrast, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near normal concentrations of cholesterol and sphingolipids.”
> “Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides.”

Source: [Vite et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4415615/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Plasma pharmacokinetic parameters after intrathecal administration

> “The pharmacokinetic parameters of adrabetadex in the plasma following intrathecal administration of LEMBAZ in patients with NPC are summarized in Table 7.”
> “Plasma AUC0-last increased in an approximately dose proportional manner and plasma Cmax increased less than dose proportionally at a dose that ranged from 200 to 900 mg.”
> “No adrabetadex accumulation in plasma or CSF was observed after repeated LEMBAZ administration.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Parameter, mean (CV%) | 200 mg | 300 mg | 600 mg | 900 mg |
| --- | --- | --- | --- | --- |
| AUC0-last (hr·mcg/mL) | “39 (19%)” | “51 (14%)” | “101 (34%)” | “167 (40%)” |
| Cmax (mcg/mL) | “2.4 (33.7%)” | “4.5 (77.3%)” | “6.3 (37%)” | “8.4 (84.3%)” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### Absorption, distribution, and elimination

> “Following intrathecal injection of LEMBAZ, the median time to peak plasma concentration (Tmax) of adrabetadex ranged from 4 to 8 hours.”
> “The absolute bioavailability of adrabetadex following intrathecal administration of LEMBAZ has not been determined.”
> “Following intrathecal administration of LEMBAZ, the mean apparent volume of distribution of adrabetadex at steady state was 61.8 L in patients with NPC.”
> “Plasma protein binding of adrabetadex is less than 10% over the concentration range from 1 to 10 micromole.”
> “The mean plasma half-life of adrabetadex was 14.7 hours, following intrathecal LEMBAZ administration.”
> “Metabolism: The metabolism of adrabetadex has not been characterized.”
> “Excretion: Adrabetadex is expected to be predominantly cleared by urinary excretion.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Cerebrospinal fluid and plasma pharmacokinetics after intracerebroventricular dosing in the NIH phase 1 trial

> “Three NPC1 subjects were admitted to the NIH Clinical Center Intensive Care Unit and an Ommaya reservoir was surgically placed on the nondominant side.”
> “Following the ICV injection of 50 mg HP-β-CD, high CSF concentrations of HP-β-CD were observed with the Cmax ranging from approximately 520 to 1,500 μg/ml in three patients (Table 4).”
> “The mean Vdss of ∼130 ml was approximately to the reported CSF volume in humans.”
> “The estimated mean t1/2 for HP-β-CD in CSF was 6.58 h based on the RP-UPLC-MS/MS method and 10.1 h based on the 2D-LC-IF-MS/MS method.”
> “The mean Cmax and AUC of HP-β-CD in plasma were less than 0.3% of the corresponding CSF PK parameters.”
> “The estimated mean t1/2 values for HP-β-CD in plasma were 12.4 h based on the RP-UPLC-MS/MS method and 15.1 h based on the 2D-LC-IF-MS/MS method.”

Source: [Jiang et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4076072/)

<a id="topic-2.1.2.6.3-4"></a>

###### Central nervous system distribution after a single intrathecal dose in cats

> “In this study, tissue distribution was investigated in normal cats that received a single 120‐mg dose of [14C]‐HP‐β‐CD (approximately 200 μCi/cat) via the cerebellomedullary cistern (CBMC) and lumbar cistern.”
> “HP‐β‐CD‐derived radioactivity penetrated into the deeper parts of the central nervous system with the highest concentration at 4 hours (403 μg Eq/g or 0.28 mM) and remained high (49.7 μg Eq/g or 0.03 mM) at 24 hours.”
> “The relatively long half‐life (11‐30 hours) in cerebral ventricles and the subarachnoid space surrounding the brain and spinal cord might contribute to the efficacy of HP‐β‐CD in NPC1 cats.”

Source: [Kao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7317750/)

<a id="topic-2.1.2.6.3-5"></a>

###### Brain distribution and duration of exposure in mice and cats: company nonclinical studies

> “Central administration distributes adrabetadex broadly throughout the CNS, reaching deep and superficial brain regions at human-equivalent doses.”
> “Sustained CNS concentrations support once-every-2 weeks dosing to counter ongoing cholesterol accumulation.”
> “Superficial, cortical regions show 2.3x higher levels of adrabetadex two weeks post-dose than deep grey matter and white matter”

Source: [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Boxed warning: hearing impairment including permanent hearing loss

> “Treatment with LEMBAZ has resulted in permanent hearing impairment.”
> “Prior to LEMBAZ use, perform a comprehensive audiology evaluation (e.g., pure tone audiometry, speech recognition, tympanometry) to establish baseline hearing levels”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss.”
> “A comprehensive hearing evaluation should be performed on patients before starting Lembaz and regularly throughout treatment, and dose adjustments may be needed based on the results of these evaluations.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.1.2.7.1-2"></a>

###### Contraindications

> “CONTRAINDICATIONS None.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-3"></a>

###### Hearing impairment: warning and precaution

> “LEMBAZ can cause hearing impairment.”
> “LEMBAZ-treated patients experienced permanent hearing impairment that ranged from mild to profound hearing loss, including in some patients with normal hearing at baseline.”
> “Observed hearing impairment predominantly impacted higher frequencies (at least 2,000 to 8,000 Hz) but hearing impairment at mid and lower frequencies (500 to 2,000 Hz) was also observed”
> “Do not increase the dosage if hearing impairment is observed as defined in subsection 2.3”
> “In patients with LEMBAZ-associated hearing impairment, there are insufficient data to determine if continuing treatment at the current dosage increases the risk of further hearing impairment or if lowering the LEMBAZ dosage reduces the risk of additional hearing impairment.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-4"></a>

###### Hearing impairment with audiometry-guided titration in Trial 3 and the expanded access program

> “Hearing Impairment: In single-arm studies (Trial 3 and an expanded access program) [see Clinical Studies (14)], the safety of LEMBAZ was assessed in 59 patients who received a starting LEMBAZ dosage of 200 mg every 2 weeks given intrathecally (less than 4 years of age), or 400 mg every 2 weeks (4 years of age or older) given intrathecally.”
> “The dosage was increased to a maximum of up to 600 mg (for patients who weighed 7 to 12 kg) or up to 900 mg (for patients who weighed more than 12 kg) given intrathecally every 2 weeks.”
> “In Trial 3 and an expanded access program which used upward titration guided by audiometry, 37% (22/59) of patients treated with LEMBAZ experienced hearing impairment”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-5"></a>

###### Ataxia: warning and precaution

> “LEMBAZ can cause ataxia, including fall, abnormal gait and/or coordination, dizziness, and hypotonia.”
> “The severity of ataxia may be associated with a higher LEMBAZ dosage.”
> “Monitor LEMBAZ-treated patients for ataxia severity.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Severe ataxia requiring hospitalization has occurred.”

Source: [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)

<a id="topic-2.1.2.7.1-6"></a>

###### Fatigue: warning and precaution

> “LEMBAZ can cause fatigue, including asthenia, fatigue, malaise, and somnolence.”
> “One patient treated with LEMBAZ 900 mg every 2 weeks required hospitalization for a severe fatigue event on the day of treatment.”
> “The severity of fatigue may be associated with a higher LEMBAZ dosage.”
> “Monitor LEMBAZ-treated patients for fatigue.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-7"></a>

###### Safety population and most common adverse reactions

> “The safety of LEMBAZ was evaluated in 141 patients with NPC (including 80 patients with NPC with neurological symptom manifestation onset at less than 6 years of age) who received at least one LEMBAZ dose given by intrathecal administration”
> “The most common adverse reactions (≥25% of patients treated with LEMBAZ and greater in LEMBAZ-treated patients than those in the sham control group) were hearing impairment, ataxia, fatigue, vomiting, back pain, headache, pyrexia, diarrhea, nausea, and cough.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “The most common side effects of Lembaz include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.1.2.7.1-8"></a>

###### Common adverse reactions through Week 52 in Trial 1 Parts A and B

> “Common adverse reactions were those reported in ≥10% of LEMBAZ-treated patients, and greater in LEMBAZ-treated patients than those in the sham control group.”
> “Subgroup of treatment arm that received LEMBAZ ≤900 mg.”
> “Hearing impairment includes other similar terms and hypoacusis, tinnitus, deafness, and abnormal tympanometry.”
> “Ataxia includes gait disturbance, fall, dizziness, dyskinesia, balance disorder, bradykinesia, abnormal coordination, dysstasia, vertigo.”
> “Fatigue includes asthenia, malaise, somnolence.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Preferred term | Adrabetadex up to 900 mg (N=32), n (%) | Sham (N=18), n (%) |
| --- | --- | --- |
| Hearing impairment | “23 (71.9)” | “8 (44.4)” |
| Ataxia | “22 (68.8)” | “5 (27.8)” |
| Fatigue | “18 (56.3)” | “5 (27.8)” |
| Vomiting | “17 (53.1)” | “3 (16.7)” |
| Back pain | “16 (50.0)” | “3 (16.7)” |
| Headache | “14 (43.8)” | “3 (16.7)” |
| Pyrexia | “13 (40.6)” | “3 (16.7)” |
| Diarrhea | “10 (31.3)” | “1 (5.6)” |
| Nausea | “8 (25.0)” | “1 (5.6)” |
| Cough | “8 (25.0)” | “4 (22.2)” |
| Contusion | “6 (18.8)” | “2 (11.1)” |
| Pain in extremity | “6 (18.8)” | “1 (5.6)” |
| Epistaxis | “5 (15.6)” | “1 (5.6)” |
| Urinary incontinence | “5 (15.6)” | “1 (5.6)” |
| Muscular weakness | “5 (15.6)” | “0 (0)” |
| Dysarthria | “4 (12.5)” | “1 (5.6)” |
| Skin abrasion | “4 (12.5)” | “1 (5.6)” |
| Nasopharyngitis | “4 (12.5)” | “2 (11.1)” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-9"></a>

###### Adverse reactions in participants less than 4 years of age

> “In Trial 3 and an expanded access program, 23 patients less than 4 years of age received a starting LEMBAZ dosage of 200 mg every 2 weeks given intrathecally, and the dosage was increased up to a maximum of 600 mg (for patients who weighed 7 to 12 kg) or 900 mg (for patients who weighed more than 12 kg) every 2 weeks given intrathecally.”
> “Adverse reactions were similar when compared to patients 4 years of age or older who received LEMBAZ at a dosage up to 900 mg in Trial 1.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-10"></a>

###### Onset and duration of ataxia and fatigue events

> “Ataxia: Of the ataxia adverse reactions that occurred in LEMBAZ-treated patients, the ataxia started within 3 days of LEMBAZ administration in 61% (107/174) of events.”
> “Ataxia adverse reactions resulted in dosage interruptions in 6% (2/32) of LEMBAZ-treated patients”
> “Fatigue: Of the fatigue adverse reactions that occurred in LEMBAZ-treated patients, the fatigue started within 3 days of LEMBAZ administration in 91% (87/96) of events.”
> “The duration of fatigue ranged from 1 to 76 days, with a median duration of 2 days”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-11"></a>

###### Aspiration pneumonia, including one fatal event after administration with sedation

> “Aspiration Pneumonia: In Trial 1 Parts A and B, 9% (3/32) of LEMBAZ-treated patients experienced aspiration pneumonia compared to 6% (1/18) of sham-treated patients.”
> “In Trial 1 Part C, a single patient experienced an aspiration event resulting in fatal aspiration pneumonia after they received LEMBAZ with sedation.”
> “It is unclear whether the aspiration pneumonia was due to LEMBAZ, sedation, and/or underlying NPC disease.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-12"></a>

###### Overdosage at 1,200 mg and 1,800 mg

> “In Trial 1 Part A [see Clinical Studies (14)], 3 patients received 1,200 mg of LEMBAZ (1.3 times maximum recommended dosage) and 3 patients received 1,800 mg of LEMBAZ (2 times the maximum recommended dosage).”
> “There was a higher rate of ataxia and fatigue, and greater severity of hearing impairment, ataxia, and fatigue in patients who received these dosages, compared to those who received the maximum recommended dose of 900 mg.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-13"></a>

###### Nonclinical carcinogenicity and mutagenicity

> “There was no evidence of a primary carcinogenic effect in mice given daily oral doses of up to 5,000 mg/kg for approximately 2 years.”
> “In rats, administration of adrabetadex at 5,000 mg/kg/day (11 times greater than the MRHD based on body surface area) for approximately 2 years increased the incidence of soft tissue combined malignant sarcoma and fibrosarcoma in males and exocrine pancreatic tumors (benign adenoma and combined benign adenoma/malignant adenocarcinoma) in females.”
> “Adrabetadex was not mutagenic or clastogenic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames), unscheduled DNA synthesis in primary rat hepatocytes, mouse lymphoma forward mutation, chromosomal aberration in human lymphocytes, and mouse micronucleus assays.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-14"></a>

###### Patient counseling on hearing impairment, ataxia, and fatigue

> “Advise patients and/or their caregivers about the risks of permanent hearing impairment with LEMBAZ treatment, and that comprehensive audiology evaluations should be performed before and during treatment”
> “Advise patients and/or their caregivers that ataxia may occur after LEMBAZ administration”
> “Advise patients and/or their caregivers that fatigue may occur after LEMBAZ administration”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-15"></a>

###### Ototoxicity of 2-hydroxypropyl-beta-cyclodextrin across species: review

> “Despite the potential health benefits, use of HPβCD has been linked to significant hearing loss in several species, including humans.”
> “Ototoxicity can occur following central or peripheral drug delivery, with either route resulting in the preferential loss of cochlear outer hair cells (OHCs) within hours of dosing.”
> “The long-term impact of HPβCD use as a maintenance drug, and the mechanism(s) of ototoxicity, are unknown.”
> “Yet, Kleptose HPB (aka VTS-270) is ototoxic in mice and humans (Davidson et al., 2016; Ory et al., 2017).”
> “Thus, seemingly innocuous doses can become devastating to the ear if administered by different routes close in time.”
> “The risk for functionally significant hearing loss before development of speech and language should be weighed carefully with potential benefits of early-life treatment of the disease.”

Source: [Crumling et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5676048/)

<a id="topic-2.1.2.7.1-16"></a>

###### Hearing threshold elevation with intracisternal administration in cats

> “An increase in hearing threshold was identified as a potential adverse effect.”
> “Our studies in the cat indicate that chronic HPβCD at therapeutic doses is always accompanied by severe hearing loss.”
> “These findings have important implications for clinical use in human patients where deafness may be an expected outcome of therapy.”

Source: [Vite et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4415615/)

<a id="topic-2.1.2.7.1-17"></a>

###### Adverse events after repeated lumbar puncture for intrathecal delivery at Rush University Medical Center

> “Of the 59 patients treated 33 (55.9%) had no adverse events ever after an LP and 26 (44.1%) had adverse effects at some time.”
> “Of the 2935 LPs, adverse events occurred after 3.3% of LPs.”
> “Adverse events most observed were headache (1.2% of LPs), nausea (0.3%), vomiting (1.0%), and back pain (1.3%).”
> “This study shows that frequent repeated LPs are possible for delivery of intrathecal therapy and can be accomplished with a very low rate of post-LP adverse events.”

Source: [Albert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37201244/)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pregnancy

> “There are no available data on the use of LEMBAZ in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
> “In animal reproduction studies, intravenous administration of adrabetadex to pregnant rats or rabbits during organogenesis at dose exposures that are 2 and 4 times greater than the maximum recommended human dose (MRHD) based on body surface area resulted in no adverse developmental effects (see Data).”
> “The background risk of major birth defects and miscarriage for females with NPC with neurological manifestations is unknown.”
> “In a pre-postnatal development study conducted in pregnant rats administered intravenous adrabetadex once daily from Gestation Day (GD) 16 through lactation at doses up to 400 mg/kg/day, there was no maternal toxicity; however, pup survival was decreased at 400 mg/kg/day (2 times the MRHD based on body surface area).”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Lactation

> “There are no data on the presence of adrabetadex in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.”
> “The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LEMBAZ and any potential adverse effects on the breastfed infant from LEMBAZ or from the underlying maternal condition.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Females and males of reproductive potential: fertility in rats

> “In a fertility and early embryonic development study, intravenous administration of adrabetadex to rats once daily from 14 days prior to mating for females and 60 days prior to mating for males, and continuing through GD 8 at doses up to 400 mg/kg/day (2 times the MRHD based on body surface area) did not adversely affect fertility.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Pediatric use: established and not established populations

> “The safety and effectiveness of LEMBAZ have been established to reduce the risk of mortality in pediatric patients, who weigh 7 kg or greater, with NPC with neurological manifestations that started at less than 6 years of age.”
> “Use of LEMBAZ for this indication is supported by evidence from integrated analyses of 1 randomized, controlled trial, 2 open-label, single-arm clinical trials, and an expanded access program compared to data from an untreated, contemporaneous, external cohort”
> “The safety and effectiveness of LEMBAZ have not been established to reduce the risk of mortality in pediatric patients with NPC who weigh less than 7 kg or in pediatric patients who developed neurological manifestations starting at 6 years of age and older.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Neurological onset at 6 years of age or older

> “The safety and effectiveness of LEMBAZ for the treatment of NPC in patients with neurological manifestations that started at 6 years of age or older has not been established”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Juvenile animal toxicity: hearing loss in cats and kidney findings in rats

> “In a cat model of NPC, juvenile cats were administered adrabetadex intrathecally at doses of 30, 60, or 120 mg every 14 days, beginning at 3 weeks of age (equivalent to a 6-month-old human infant) and continuing through approximately 24 weeks of age.”
> “Progressive hearing loss was observed in all treatment groups beginning at 8 weeks of age and increasing in a dose-dependent manner with repeated dosing.”
> “Hearing loss was irreversible following treatment cessation, with no improvement in hearing threshold observed up to 12 weeks after the last dose”
> “Dose-related increases in kidney weights that correlated with slight to moderate diffuse microvacuolation of the cortical tubules were observed at 200 mg/kg/day or more.”
> “Hearing was not assessed in this study.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

###### Geriatric use

> “Clinical studies of LEMBAZ did not include patients 65 years of age and older to determine if they respond differently from younger adult patients.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.8-8"></a>

###### Renal and hepatic impairment

> “Patients with Renal or Hepatic Impairment: No clinical studies have been conducted to evaluate the pharmacokinetics of adrabetadex in patients with renal or hepatic impairment.”
> “Systemic exposure of adrabetadex is expected to be higher in patients with renal impairment, which is not considered clinically significant.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Adrabetadex

<a id="topic-2.1.2.9.1-1"></a>

###### In vitro cytochrome P450 and transporter substrate studies

> “CYP Enzymes: Adrabetadex is not a substrate or inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4, or an inducer of CYP1A2, 2B6, or 3A4.”
> “Transporter Systems: Adrabetadex is not a substrate of organic anion transporter (OAT)1 and OAT3, organic cation transporter (OCT)2, multidrug and toxin extrusion protein (MATE)1, MATE2-K, OATP1B1, OATP1B3, BCRP, or P-glycoprotein (P-gp).”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Adrabetadex on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### In vitro transporter inhibition

> “Adrabetadex is not an inhibitor of bile salt export pump (BSEP), OAT1, OAT3, OCT2, MATE1, MATE2-K, OATP1B3, or P-gP transporters.”
> “Adrabetadex inhibits OATP1B1 and BCRP transporters, but the clinical significance is unknown.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### Binding of arimoclomol and levacetylleucine by adrabetadex: company in silico and in vitro studies

> “Molecular docking and molecular dynamics simulations predicted no stable binding of arimoclomol or NALL within the guest cavity of adrabetadex (Table 1).”
> “Adrabetadex showed very weak or no binding affinity to arimoclomol and NALL in direct binding measurement.”
> “Consistent with these findings, ITC demonstrated no detectable interaction under conditions in which adrabetadex was bound to cholesterol.”
> “No evidence of drug-drug interaction was observed, supporting evaluation of complementary therapies in addition to adrabetadex treatment.”

Source: [Burchard et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P02-Nonclinical.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Recommended starting dosage by age

> “Recommended starting LEMBAZ dosage in patients who weigh 7 kg or greater is the following (2.2):”
> “Less than 6 months of age is 100 mg every two weeks.”
> “6 months of age to less than 4 years of age is 200 mg every two weeks.”
> “4 years of age or older is 400 mg every two weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-2"></a>

###### Upward titration and maximum dosage by weight

> “See Table 1 for the recommended starting dosage and the recommended maximum dosage for LEMBAZ in patients who weigh 7 kg or greater.”
> “After at least 2 doses at each dosage level (a dosage level consists of the same dose of LEMBAZ given two weeks apart), titrate the LEMBAZ dosage upward in 100-mg to 200-mg increments as tolerated, up to the maximum recommended dosage.”
> “If 7 kg to less than 12 kg, maximum dosage is 600 mg every two weeks.”
> “If 12 kg or more, maximum dosage is 900 mg every two weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Lembaz dosing schedule: 1 intrathecal bolus injection every 2 weeks”
> “Give at least 2 doses at each dosage level, then step up as tolerated to the weight-based maximum, each step guided by audiology.”

Source: [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)

<a id="topic-2.1.2.10.1-3"></a>

###### Dosage modifications for hearing loss: audiology schedule

> “During LEMBAZ treatment to determine the subsequent dosage level, repeat the comprehensive audiology evaluation 1 to 2 weeks after the first LEMBAZ dose at each dosage level but before the next dose, and then 1 to 2 weeks after the second LEMBAZ dose at each dosage level but before the next dose (see Table 2).”
> “When a patient remains at the same LEMBAZ dosage level for 2 consecutive doses or has reached the maximum dosage, perform comprehensive audiology evaluations at one-month intervals until 3 consecutive, stable audiology results are obtained, and then repeat the comprehensive audiology evaluation every 12 months.”
> “In patients with LEMBAZ-associated hearing impairment, there are insufficient data to determine if continuing LEMBAZ treatment at the current dosage level increases the risk of further hearing impairment or if lowering the LEMBAZ dosage reduces the risk of further hearing impairment”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-4"></a>

###### Dosage titration recommendations based on audiology results

| Baseline hearing status | Result permitting an increase (first criterion) | Result permitting an increase (alternative criterion) | Result precluding an increase |
| --- | --- | --- | --- |
| No baseline hearing impairment | “No hearing impairment observed at frequencies below 4,000 Hz” | “Hearing impairment observed but with a hearing threshold less than or equal to 40 dB HL at frequencies below 4,000 Hz” | “Hearing impairment with a threshold greater than 40 dB HL at frequencies below 4,000 Hz (hearing impairment in the speech hearing range)” |
| Baseline mild to moderate hearing impairment | “No hearing threshold shift at 2 consecutive frequencies below 4,000 Hz” | “Hearing threshold shift that is not greater than 15 dB at 2 consecutive frequencies below 4,000 Hz” | “Hearing threshold shift of greater than 15 dB at 2 consecutive frequencies below 4,000 Hz” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-5"></a>

###### Dosage modifications for ataxia or fatigue

> “In patients with severe ataxia or fatigue associated with LEMBAZ treatment, consider reducing the LEMBAZ dosage”
> “If the LEMBAZ dosage is decreased due to severe ataxia or fatigue and the ataxia or fatigue becomes mild or resolves, then consider increasing the LEMBAZ dosage.”
> “Subsequently, if the ataxia or fatigue worsens in severity, then consider decreasing LEMBAZ dosing.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.1-6"></a>

###### Missed doses

> “If one or more LEMBAZ doses are missed, restart LEMBAZ treatment as soon as possible, maintaining the 2-week interval between intrathecal administrations thereafter.”
> “Do not administer an extra LEMBAZ dose to compensate for a missed dose.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Baseline audiology before the first dose

> “Prior to initiation of LEMBAZ treatment, perform a baseline comprehensive audiology evaluation (e.g., pure tone audiometry, speech recognition, tympanometry) to establish baseline hearing levels”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Week labels are illustrative. The label specifies dosing every 2 weeks, with audiology 1 to 2 weeks after the first and second dose at each dosage level.”

Source: [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Route and administering provider

> “Administer LEMBAZ intrathecally over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “A trained healthcare provider gives Lembaz as an injection directly into the spinal canal”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

> “LEMBAZ is for intrathecal use only (injected into the fluid around the spinal cord).”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.10.2-3"></a>

###### Preparation and dilution

> “Visually inspect the solution in the vials for particulate matter and discoloration.”
> “Withdraw the required volume of LEMBAZ from the vial and discard unused contents of the vial.”
> “Dilute LEMBAZ with 0.9% Sodium Chloride Injection (preservative free) to a total administration volume of 3 mL, 5 mL, or 10 mL based on patient’s weight (see Tables 3, 4, and 5, respectively).”
> “For patients who weigh 7 kg to less than 12 kg on the LEMBAZ 600-mg dose, the LEMBAZ dose volume of 3 mL is administered undiluted.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-4"></a>

###### Storage of the diluted solution

> “If the diluted LEMBAZ solution is not administered immediately, store it at room temperature at 20°C to 25°C (68°F to 77°F).”
> “Administer LEMBAZ within 8 hours or discard.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-5"></a>

###### Premedication: local anesthesia and sedation

> “Consider the following concomitant therapy prior to intrathecal administration of LEMBAZ:”
> “Apply local anesthetic (topical and subcutaneous lidocaine) to the intended injection site.”
> “Consider sedation as indicated by the clinical condition of the patient.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-6"></a>

###### Lumbar puncture technique and positioning after injection

> “If there is difficulty accessing the intrathecal space, consider imaging to guide intrathecal administration of LEMBAZ.”
> “Prior to LEMBAZ administration, remove up to 5 mL of cerebrospinal fluid (CSF).”
> “Administer LEMBAZ as an intrathecal bolus injection over 1 to 2 minutes using a spinal needle.”
> “Do not administer LEMBAZ in areas of the skin where there are signs of infection or inflammation.”
> “After administration, keep patients in the Trendelenburg position (head down at 15 to 30 degrees) for approximately 40 minutes.”
> “If unable to tolerate the Trendelenburg position, keep the patient flat as tolerated for about 40 minutes.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.10.2-7"></a>

###### Needles and anesthesia used for repeated lumbar punctures at Rush University Medical Center

> “Intrathecal delivery of 2-hydroxypropyl-beta-cyclodextrin (VTS-270, adrabetadex) by lumbar puncture (LP) has been performed on a biweekly schedule for over nine years for the treatment of Niemann-Pick type C1 (NPC1) at Rush University Medical Center.”
> “Over this time 59 patients with NPC1 have been treated with 2935 infusions, performed with either a 22-G 3-inch Whitacre or a 22-G 2-inch Gertie Marx atraumatic needles, with or without general anesthesia.”

Source: [Albert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37201244/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial availability and treatment site coordination

> “Finding an appropriate treatment site is critical for families.”
> “A dedicated Beren Family Access Manager (FAM) will serve as a single point of contact, working directly with families to help identify an appropriate site of care, ideally close to home, and coordinate access to treatment.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.1.2.11-2"></a>

###### Transition from the Expanded Access Program to commercial treatment

> “If your child is in the Expanded Access Program, a Beren Family Access Manager can begin helping you plan the transition to commercial treatment immediately, even before LEMBAZ is available at those sites.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

<a id="topic-2.1.2.11-3"></a>

###### Distribution: exclusive specialty distributor

> “Lembaz is exclusively available through CuraScript SD by Evernorth”
> “Contact CuraScript SD by Evernorth to begin ordering Lembaz”

Source: [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf)

<a id="topic-2.1.2.11-4"></a>

###### Medical buy-and-bill and billing codes

> “This brochure is designed to support your practice or site of care with accurate and efficient claim preparation for Lembaz in medical buy-and-bill settings.”
> “At this time, Lembaz does not have a product-specific HCPCS code.”
> “C9399, J3490, and J3590 are not interchangeable.”

Source: [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)

| Code | Description |
| --- | --- |
| HCPCS C9399 | “Unclassified drugs or biologics. Hospital outpatient/OPPS-oriented use; payer and facility validation required.” |
| HCPCS J3490 | “Unclassified drugs. Professional/CMS-1500 or payer-directed miscellaneous drug pathway.” |
| ICD-10-CM E75.242 | “Niemann-Pick disease, type C” |
| CPT 62329 | “Injection of diagnostic or therapeutic substance into the subarachnoid (intrathecal) space, including needle placement and imaging guidance (fluoroscopy or CT).” |
| CPT 00635 | “Anesthesia for procedures in lumbar region (diagnostic or therapeutic lumbar puncture)” |

Source: [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)

<a id="topic-2.1.2.11-5"></a>

###### Prior authorization documentation

> “Confirm the patient’s benefits and the health plan’s requirements for the prior authorization (PA), treatment location, coding, billing, and patient costs”
> “Relevant clinical documentation, including a complete baseline audiology evaluation before treatment”
> “Documentation of prior Expanded Access Program (EAP) participation, if applicable”
> “Confirm that the request lists the planned dose, number of vials or billing units, dosing frequency, NDC, and any procedure or HCPCS codes required by the plan”

Source: [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf)

> “The following document includes possible content to be used as a letter of medical necessity in support of a patient receiving Lembaz™ (adrabetadex) for the treatment of Niemann-Pick disease, type C, with neurological manifestations that started at less than 6 years of age.”

Source: [LEMBAZ letter of medical necessity template (2026)](https://lembazrx.com/wp-content/uploads/medical-necessity-template.pdf)

<a id="topic-2.1.2.11-6"></a>

###### Enrollment form

> “For Specialty Pharmacy prescriptions, I authorize Lembaz™ Family Support to transmit the above prescription to the appropriate Specialty Pharmacy for my patient.”
> “Has an Audiology Test Been Completed?”

Source: [LEMBAZ patient enrollment form (2026)](https://lembazrx.com/wp-content/uploads/patient-enrollment-form.pdf)

<a id="topic-2.1.2.11-7"></a>

###### Patient support program: LEMBAZ Family Support

> “The LEMBAZ Family Support program offers comprehensive financial assistance and personalized support through a dedicated Beren team that provides one-on-one help navigating the treatment journey.”
> “Out-of-pocket assistance: full out-of-pocket assistance for eligible families, so that there is no out-of-pocket cost to families”
> “Insurance & logistics navigation: dedicated Beren case managers help coordinate insurance coverage, travel logistics and other practical aspects of treatment to enable patients to start and stay on therapy”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

> “If you have commercial or private insurance, you may be able to pay $0 for Lembaz and services associated with your treatment.”
> “Eligible families may qualify for help with Lembaz costs through the Patient Assistance Program (PAP).”
> “Bridge support may be available to help your loved one get started while coverage is being worked out.”

Source: [LEMBAZ caregiver website (2026)](https://lembazrx.com/)

<a id="topic-2.1.2.11-8"></a>

###### Out-of-pocket, bridge, and patient assistance program terms

> “The Program is not valid for patients enrolled in any state or federal government program, including, but not limited to, Medicaid/Managed Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico government insurance, or any state pharmaceutical assistance program.”
> “Not eligible for the Program if rare disease is a benefit exclusion or carve out.”
> “This Program may not be redeemed for more than the approved dose, max of 26 doses per year, given as an IT every 2 weeks.”
> “The Program is valid for 2 years and requires re-enrollment in the 21st month of the Program.”
> “If you may be eligible for Medicaid, you will be required to provide documentation of a Medicaid final denial before being evaluated for PAP eligibility.”

Source: [LEMBAZ Family Support terms and conditions (2026)](https://lembazrx.com/Co-Pay)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Combination treatment: 2025 international consensus guideline

> “Statement #18: Combination treatment should be considered for all patients with a confirmed diagnosis of NPC.”
> “However, available treatments have distinct mechanisms of action, making combination therapy an approach that targets multiple aspects of NPC neuropathology”
> “Despite this, it is important to note that healthcare system resource limitations often restrict access to combination treatments.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.1.2.12-2"></a>

###### Concomitant arimoclomol, levacetylleucine, and miglustat in the expanded access program

> “The program permitted concomitant use of other NPC therapies, arimoclomol or levacetylleucine, after their approval, allowing evaluation of adrabetadex administered concomitantly with arimoclomol, levacetylleucine, or both.”
> “At the data cutoff of March 27, 2026, 33 participants had received adrabetadex with arimoclomol and/or levacetylleucine.”
> “All 33 participants received adrabetadex, while 27 (81.8%) received levacetylleucine, 21 (63.6%) arimoclomol, and 20 (60.6%) miglustat; 10 participants were exposed to all four therapies.”
> “A total of 5 participants received arimoclomol before U.S. approval and later added treatment with adrabetadex.”
> “Most participants initiated adrabetadex prior to complementary therapies, with arimoclomol and/or levacetylleucine frequently added after adrabetadex (when they became commercially available) rather than used instead of adrabetadex.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Safety of combination therapy in the expanded access program

> “Of participants treated with adrabetadex ± miglustat only (n=53), 90.6% experienced at least one TEAE compared to 100% of those who started adrabetadex first, followed by levacetylleucine and/or arimoclomol (n=28) and 69.7% for those who were exposed to combination therapy at any point (n=33).”
> “Safety findings were generally consistent with the established adrabetadex safety profile, with differences in treatment exposure and observation time limiting comparisons across groups.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Combination with arimoclomol or levacetylleucine in vitro: company nonclinical study

> “Other therapies for NPC including arimoclomol and N-acetyl-L-leucine (NALL; levacetylleucine), have distinct mechanisms and may address complementary aspects of the disease biology.”
> “To evaluate a) the binding interactions between adrabetadex, arimoclomol, and NALL and b) the in vitro effects of adrabetadex, arimoclomol, and NALL monotherapy, and adrabetadex in combination with arimoclomol or NALL on oligodendrocyte (OL) proliferation, synaptic network growth, and myelination of mature neurons.”
> “Combination of adrabetadex with arimoclomol or NALL achieved comparable effects at substantially lower concentrations than monotherapy, supporting mechanistic compatibility between adrabetadex and therapies with complementary mechanisms.”

Source: [Burchard et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P02-Nonclinical.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Adrabetadex on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Service quality metrics for lysosomal storage disorders: time to disease-modifying therapy, palliative care review, and advance care planning

> “Mean length of time from decision to treat to commencement of a disease modifying therapy (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) and chaperone).”
> “Percentage of patients who died (excluding sudden unexpected deaths) in the reporting year who had been reviewed by the palliative care team in 24 months prior”
> “The proportion of patients who died in the reporting year who had an advanced care plan in place.”

Source: [NHS England Specialised Services Quality Dashboard lysosomal storage disorders metric definitions (2022)](https://www.england.nhs.uk/wp-content/uploads/2022/04/Lysosomal-Storage-Disorders-LSD-All-Ages.pdf)

<a id="topic-2.1.2.13-2"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Approval basis and labeled population compared with the two other approved NPC treatments

> “Lembaz marks the FDA’s third approval for NPC after IntraBio’s Aqneursa and Zevra’s Miplyffa were approved in the same month in 2024.”
> “To Lembaz’s advantage, it’s the only treatment approved based on survival data.”
> “The other two treatments were cleared on data showing they improved disease progression and neurological function.”
> “Lembaz is also indicated for the smallest of patients starting at 15 pounds compared to 33 pounds with Aqneursa and two years of age with Miplyffa.”

Source: [Fierce Pharma LEMBAZ approval report (2026)](https://www.fiercepharma.com/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease)

<a id="topic-2.1.2.14-2"></a>

###### Arimoclomol: U.S. indication

> “MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.”
> “There were insufficient data to determine the effectiveness of the use of MIPLYFFA without miglustat for the treatment of neurological manifestations in patients with NPC.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Arimoclomol: recommended oral dosage by actual body weight, in combination with miglustat

| Actual body weight | Prescribing information |
| --- | --- |
| 8 kg to 15 kg | “8 kg to 15 kg, is 47 mg three times a day” |
| More than 15 kg to 30 kg | “15 kg to 30 kg, is 62 mg three times a day” |
| More than 30 kg to 55 kg | “30 kg to 55 kg, is 93 mg three times a day” |
| More than 55 kg | “55 kg, is 124 mg three times a day” |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

> “The recommended oral dosage of MIPLYFFA, in combination with miglustat, for patients with an actual body weight of:”
> “Administer MIPLYFFA with or without food.”
> “If a dose of MIPLYFFA is missed, advise the patient to skip the missed dose and to resume taking the prescribed dose at the next scheduled time.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Arimoclomol: dosage in renal impairment

> “The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥ 50 mL/minute is the same as the recommended dosage in patients with normal renal function”
> “For patients with an eGFR ≥ 15 to < 50 mL/minute, the recommended oral dosage of MIPLYFFA, in combination with miglustat, for patients with an actual body weight of”
> “8 kg to 15 kg, is 47 mg two times a day”
> “55 kg, is 124 mg two times a day”
> “The pharmacokinetics of arimoclomol have not been evaluated in patients with eGFR < 15 mL/minute.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Arimoclomol: dosage forms, packaging, and national drug codes

> “Capsules: 47 mg, 62 mg, 93 mg and 124 mg of arimoclomol.”
> “MIPLYFFA (arimoclomol) capsules are supplied in high-density polyethylene (HDPE) bottles with child-resistant closure as follows:”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

| Strength | Package configuration | NDC |
| --- | --- | --- |
| 47 mg | “Bottle of 90 capsules” | “72542-147-01” |
| 62 mg | “Bottle of 90 capsules” | “72542-162-01” |
| 93 mg | “Bottle of 90 capsules” | “72542-193-01” |
| 124 mg | “Bottle of 90 capsules” | “72542-124-01” |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Arimoclomol: oral and feeding tube administration

> “Swallow MIPLYFFA whole. However, for patients who have difficulty swallowing capsules, administer MIPLYFFA in one of two ways:”
> “Carefully open the capsule and sprinkle the entire contents into 15 mL of water or apple juice or 15 mL of soft food (e.g., applesauce, pudding, or yogurt).”
> “Carefully open the capsule and sprinkle the entire contents into 20 mL of water.”
> “Administer the entire mixture immediately via feeding tube.”
> “Flush the feeding tube with 5 mL of water after administration.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Arimoclomol: warnings and precautions

> “Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1”
> “The reactions occurred within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions.”
> “Based on findings from animal reproduction studies, MIPLYFFA may cause embryofetal harm when administered during pregnancy.”
> “Across clinical trials of MIPLYFFA consisting of patients with NPC, healthy subjects, and patients with other diseases, there were mean increases in serum creatinine of 10% to 20% compared to baseline.”
> “During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function such as BUN, cystatin C, or measured GFR.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Arimoclomol: adverse reactions in Trial 1

> “The safety of MIPLYFFA was evaluated in a randomized, double-blind, placebo-controlled, 12-month trial (Trial 1), which included 50 patients 2 to 19 years old with NPC”
> “Patients received weight-adjusted doses of MIPLYFFA (31 to 124 mg orally three times daily); 28 of the patients were exposed to MIPLYFFA for one year. In Trial 1, 78% of patients received miglustat.”
> “The most common adverse reactions in Trial 1 (≥ 15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.”
> “Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients).”
> “Serious adverse reactions reported in MIPLYFFA-treated patients in Trial 1 were hypersensitivity reactions including urticaria and angioedema.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Arimoclomol: adverse reactions in at least 8% of treated participants who also received miglustat in Trial 1

| Adverse reaction | MIPLYFFA with miglustat, N=26, n (%) | Placebo with miglustat, N=13, n (%) |
| --- | --- | --- |
| Upper respiratory tract infection | “8 (31)” | “2 (15)” |
| Diarrhea | “6 (23)” | “3 (23)” |
| Decreased weight | “4 (15)” | “0” |
| Lower respiratory tract infection | “3 (12)” | “1 (8)” |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Arimoclomol: drug interaction with OCT2 substrates

> “Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates”
> “When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Arimoclomol: pediatric and geriatric use

> “The safety and effectiveness of MIPLYFFA have not been established in pediatric patients younger than 2 years of age.”
> “NPC is largely a disease of pediatric and young adult patients. Clinical trials of MIPLYFFA in combination with miglustat in patients with NPC did not include patients aged 65 years or older.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

###### Levacetylleucine: U.S. indication in Niemann-Pick disease type C

> “AQNEURSA® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-13"></a>

###### Levacetylleucine: recommended dosage by body weight

| Body weight | Morning dose | Afternoon dose | Evening dose |
| --- | --- | --- | --- |
| 15 kg to less than 25 kg | “1 gram” | “No Dose” | “1 gram” |
| 25 kg to less than 35 kg | “1 gram” | “1 gram” | “1 gram” |
| 35 kg or more | “2 grams” | “1 gram” | “1 gram” |

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-14"></a>

###### Levacetylleucine: basis of the dosage and packet strength

> “The recommended dosage of AQNEURSA to be administered orally, with or without food, is based on the patient’s actual body weight (kg), as shown in Table 1”
> “One AQNEURSA packet contains 1 gram levacetylleucine.”
> “For AQNEURSA doses of 2 grams, prepare two packets individually”
> “The approved dosage regimen is based on body weight and not age.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-15"></a>

###### Levacetylleucine: granules for oral suspension, strength and appearance

> “For oral suspension: 1 gram levacetylleucine in a unit-dose packet.”
> “For oral suspension: 1 gram levacetylleucine as white to off-white strawberry flavored granules in a unit-dose packet.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-16"></a>

###### Levacetylleucine: warning for embryo-fetal toxicity

> “Based on findings from animal reproduction studies, AQNEURSA may cause embryo-fetal harm when administered during pregnancy.”
> “Administration of levacetylleucine to pregnant rats and rabbits during the period of organogenesis caused an increase in embryo-fetal death (post implantation loss/resorption) and skeletal malformations at a dose that was approximately 1.4-fold and 6-fold, respectively, the maximum recommended human dose (MRHD) of 4 g/day of levacetylleucine (based on body surface area).”
> “The decision to continue or discontinue AQNEURSA treatment during pregnancy should consider the female’s need for AQNEURSA, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease.”
> “For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with AQNEURSA.”
> “Advise females of reproductive potential to use effective contraception during treatment with AQNEURSA and for 7 days after the last dose if AQNEURSA is discontinued”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-17"></a>

###### Levacetylleucine: adverse reactions in NPC, safety population and exposure in Trial 1

> “The safety of AQNEURSA was evaluated in Trial 1, which included a total of 60 patients with Niemann-Pick disease Type C (NPC), in a placebo-controlled, randomized, crossover trial”
> “The mean (SD) treatment duration of AQNEURSA was 86.2 (4.7) days (69 min, 97 max); the mean (SD) treatment duration on placebo was 87.3 (4.8) days (78 min, 113 max).”
> “In NPC, the most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-18"></a>

###### Levacetylleucine: adverse reactions in NPC at an incidence of 5% or more in Treatment Period I of Trial 1

| Adverse reaction | AQNEURSA, N=30, n (%) | Placebo, N=30, n (%) |
| --- | --- | --- |
| Upper respiratory tract infection | “5 (17)” | “1 (3)” |
| Abdominal pain | “2 (7)” | “0 (0)” |
| Dysphagia | “2 (7)” | “0 (0)” |
| Vomiting | “2 (7)” | “0 (0)” |

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-19"></a>

###### Levacetylleucine: rosacea and thrombocytopenia in NPC Trial 1

> “One patient experienced an exacerbation of rosacea during Trial 1 that responded to treatment. AQNEURSA was not discontinued.”
> “Thrombocytopenia with platelets < 100 10^3 cells/µL was observed in four patients during Treatment Period 1 of Trial 1, all of whom were receiving miglustat for 42 days or longer at the time of enrollment.”
> “In two of these patients, the thrombocytopenia was present at baseline. In the other two patients, the thrombocytopenia developed during Trial 1.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-20"></a>

###### Levacetylleucine: pediatric use in NPC and supporting pharmacokinetic data

> “The safety and effectiveness of AQNEURSA for the treatment of NPC have been established in 23 pediatric patients weighing ≥15 kg in Trial 1.”
> “Use of AQNEURSA for this indication is supported by evidence from one adequate and well-controlled study in adults and pediatric patients weighing ≥15 kg with additional pharmacokinetic data from 40 adults and 17 pediatric patients who participated in two open-label studies”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-21"></a>

###### Miglustat: U.S. labeled indication limited to type 1 Gaucher disease

> “ZAVESCA is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).”
> “Capsules: 100 mg of miglustat, white opaque hard gelatin capsules with “OGT 918” printed in black on the cap and “100” printed in black on the body.”

Source: [ZAVESCA prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021348s016lbl.pdf)

<a id="topic-2.1.2.14-22"></a>

###### Miglustat: European Union indication and dosage in Niemann-Pick type C disease

> “Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease (see sections 4.4, and 5.1).”
> “Therapy should be directed by physicians who are knowledgeable in the management of Gaucher disease or Niemann-Pick type C disease, as appropriate.”
> “The recommended dose for the treatment of adult patients with Niemann-Pick type C disease is 200 mg three times a day.”
> “The recommended dose for the treatment of adolescent patients (12 years of age and above) with Niemann-Pick type C disease is 200 mg three times a day.”
> “Dosing in patients under the age of 12 years should be adjusted on the basis of body surface area as illustrated below:”
> “There is limited experience with the use of Zavesca in Niemann-Pick type C disease patients under the age of 4 years.”
> “Zavesca can be taken with or without food.”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-23"></a>

###### Miglustat: European Union dose by body surface area in Niemann-Pick type C disease, patients under 12 years

| Body surface area (m2) | Recommended dose |
| --- | --- |
| More than 1.25 | “200 mg three times a day” |
| More than 0.88 to 1.25 | “200 mg twice a day” |
| More than 0.73 to 0.88 | “100 mg three times a day” |
| More than 0.47 to 0.73 | “100 mg twice a day” |
| 0.47 or less | “100 mg once a day” |

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-24"></a>

###### Miglustat: European Union dose in renal impairment

> “Pharmacokinetic data indicate increased systemic exposure to miglustat in patients with renal impairment.”
> “Use in patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m2) is not recommended (see sections 4.4 and 5.2).”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-25"></a>

###### Miglustat: European Union contraindications, warnings, and precautions

> “Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.”
> “Approximately 37% of patients in clinical trials in type 1 Gaucher disease, and 58% of patients in a clinical trial in Niemann-Pick type C disease reported tremor on treatment.”
> “Gastrointestinal events, mainly diarrhoea, have been observed in more than 80% of patients, either at the outset of treatment or intermittently during treatment (see section 4.8).”
> “Cases of Crohn’s disease have been reported post-marketing in Niemann-Pick type C disease patients treated with Zavesca.”
> “Reliable contraceptive methods should be maintained while male patients are taking Zavesca and for 3 months following discontinuation.”
> “The benefit of treatment with Zavesca for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be re-appraised after at least 1 year of treatment with Zavesca.”
> “In patients included in the clinical trial, 40%-50% had platelet counts below the lower limit of normal at baseline. Monitoring of platelet counts is recommended in these patients.”
> “Growth should be monitored in paediatric and adolescent patients during treatment with Zavesca; the benefit/risk balance should be re-assessed on an individual basis for continuation of therapy.”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-26"></a>

###### Miglustat: most common adverse reactions in European Union labeling

> “The most common adverse reactions reported in clinical studies with Zavesca were diarrhoea, flatulence, abdominal pain, weight loss and tremor (see section 4.4).”
> “The most common serious adverse reaction reported with Zavesca treatment in clinical studies was peripheral neuropathy (see section 4.4).”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-27"></a>

###### Remibetadex (intravenous hydroxypropyl-beta-cyclodextrin, Trappsol Cyclo): investigational status and proposed use

> “Potential to become treatment for the neurovisceral manifestations of NPC in adult and pediatric patients from birth (proposed indication)”
> “Only investigational NPC therapy given IV – addressing visceral disease, studied from birth, and not dependent on swallowing”
> “Two oral NPC therapies approved in the U.S. in 2024”
> “Remibetadex is an investigational drug that has not been approved by FDA or any other regulatory authority, and its pricing has not been established.”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Guideline definition: autosomal recessive neurovisceral lysosomal disorder

> “Statement #1: NPC is a progressive and life‐limiting autosomal recessive, neurovisceral lysosomal disorder caused by pathological variants in either NPC1 or NPC2.”
> “Variants in these genes are associated with abnormal endosomal‐lysosomal trafficking, resulting in the accumulation of unesterified cholesterol and other lipids in the lysosomes.”
> “Disease onset varies, ranging from antenatally to throughout the lifespan.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.1-2"></a>

###### Genetic basis and diagnostic definition

> “The diagnosis of NPC is established in a proband with suggestive findings and biallelic pathogenic variants in either NPC1 or NPC2 identified by molecular genetic testing.”
> “The terms Niemann-Pick disease type C1 (NPC1) and Niemann-Pick disease type C2 (NPC2) are now preferred because they correspond with the associated genes (NPC1 and NPC2).”
> “The term Niemann-Pick disease type D describes a genetic isolate from Nova Scotia that is biochemically and clinically indistinguishable from NPC and that also results from biallelic pathogenic variants in NPC1.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.1-3"></a>

###### Proportion of cases attributed to NPC1 and NPC2

| Gene | Proportion of NPC attributed to pathogenic variants in gene |
| --- | --- |
| NPC1 | “95%” |
| NPC2 | “5%” |

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.1-4"></a>

###### Autosomal recessive inheritance and recurrence risk

> “NPC is inherited in an autosomal recessive manner.”
> “If both parents are known to be heterozygous for an NPC-related pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants.”
> “The NPC phenotype usually runs true in families; that is, if the proband has early-onset disease, sibs who inherit biallelic pathogenic variants will have a similar clinical course.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.1-5"></a>

###### Genetic etiology and clinical forms by age at onset

> “Niemann-Pick disease type C (NPC) is an autosomal recessive disorder caused by pathogenic variants in NPC1 (OMIM 257220, HGNC:7897) or NPC2 (OMIM 607625, HGNC:14537)”
> “The infantile-onset form of NPC is characterized by cholestatic liver disease, hepatosplenomegaly, and pulmonary infiltrates, whereas later presentations include progressive neurologic symptoms, including cognitive impairment, cerebellar ataxia, psychiatric manifestations, and seizures, in addition to visceral disease.”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

<a id="topic-2.2.1.1-6"></a>

###### Definition of infantile-onset NPC: sponsor statement

> “Infantile-onset NPC (I-NPC) refers to NPC in infants and children who first experience neurological symptoms before six years of age.”
> “Niemann-Pick disease, type C (NPC) is a rare, autosomal-recessive, severe, heterogeneous, neurodegenerative disorder caused by pathogenic variants in the NPC1 (~95% of cases) or NPC2 genes, leading to impaired intracellular cholesterol trafficking resulting in progressive neurological decline and premature mortality.”

Source: [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)

<a id="topic-2.2.1.1-7"></a>

###### Classification by age at onset of neurological manifestations

> “Nevertheless, NPC is best classified according to the age at onset of neurological manifestations, as this correlates with prognosis, as follows:”
> “Pre/perinatal (< 2 months)”
> “Early infantile (2 months–2 years)”
> “Late infantile (2–6 years)”
> “Juvenile (6–16 years)”
> “Adult (> 16 years)”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.1-8"></a>

###### Alternative onset-category thresholds in a registry-based survival study

> “Miglustat‐treated and untreated patients overall and within sub‐groups according to age‐at‐neurological‐onset, that is, early infantile‐onset (<2 years), late infantile‐onset (2 to <6 years), juvenile‐onset (6 to <15 years), and adolescent/adult‐onset (≥15 years) were analysed and compared.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Niemann-Pick disease type C

<a id="topic-2.2.1.2.1-1"></a>

###### Guideline incidence estimate and range across national studies

> “Statement #2: NPC disease is ultra‐rare, with an estimated incidence of one case per 100 000 live births.”
> “The disease is pan‐ethnic, with at least 95% of all cases attributed to variants in NPC1, and the remainder in NPC2.”
> “The milder forms of the disease remain underdiagnosed.”
> “Retrospective, national expert center‐based studies from Australia, the Netherlands, the UK, Portugal, the Czech Republic, France, and the United Arab Emirates have reported an annual incidence varying between 0.25 and 2.20 per 100 000 live births”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence predicted from exome sequencing data sets

> “We determined a combined incidence of classical NPC of 1/89,229 or 1.12 affected patients per 100,000 conceptions, but predict incomplete ascertainment of a lateonset phenotype of NPC1.”
> “Our data suggests an incidence rate for NPC1 and NPC2 of 1/92,104 and 1/2,858,998, respectively.”
> “However, evaluation of common NPC1 variants, suggests that there may be a late-onset NPC1phenotype with a markedly higher incidence on the order of 1/20,000–39,000.”

Source: [Wassif et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4486368/)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence in France

> “The incidence of NPC in France has been calculated at about 1:120,000, based on the number of individuals diagnosed postnatally in a ten-year period versus the number of births during the same period.”
> “When pregnancies that did not result in a live-born infant were included, a slightly higher incidence of 1:100,000 was found”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.2.1-4"></a>

###### Minimal incidence and birth prevalence by country

> “Niemann-Pick C disease (NP-C) is a neurovisceral atypical lysosomal lipid storage disorder with an estimated minimal incidence of 1/120 000 live births.”
> “Estimates of birth prevalence ranging between 0.66 and 0.83 per 100,000 were proposed for France, the UK and Germany based on diagnoses made in the laboratory of the author over the period 1988-2002”

Source: [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)

<a id="topic-2.2.1.2.1-5"></a>

###### Birth prevalence by country and in Quebec

> “Elsewhere in the world, the prevalence of NP-C for 100,000 live births is 0.47 in Australia44, 0.91 in Czech Republic15, 2.2 in Northern Portugal4, 0.35 in the Netherlands3, 0.82 for France5, 0.78 for the United Kingdom45 and 1.12 for the United States of America (USA)46.”
> “By combining these different prevalences, we obtain an average of 0.95 cases per 100,000 births.”
> “We estimate a prevalence of 0.61 per 100,000 births in Quebec.”

Source: [Labrecque et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8604933/)

<a id="topic-2.2.1.2.1-6"></a>

###### Birth incidence in Australia

> “Niemann–Pick disease type C (NP‐C) is the fifth most prevalent lysosomal disorder in Australia (1 in 112 000 live births).”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.2.1-7"></a>

###### Estimated new cases per year in the United States

> “Based on the published literature, there are an estimated 42 new NPC cases per year.”

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)

<a id="topic-2.2.1.2.1-8"></a>

###### Distribution of clinical forms in eight national and international cohorts

| Cohort | Acute perinatal form (%) | Early infantile neurological onset (%) | Late infantile neurological onset (%) | Juvenile neurological onset (%) | Adult neurological onset (%) | Total no. |
| --- | --- | --- | --- | --- | --- | --- |
| France and European countries | “12” | “30” | “23” | “30” | “5” | “125” |
| Spain | “7” | “37” | “21” | “25” | “11” | “57” |
| Italy | “7” | “26” | “32” | “23” | “12” | “43” |
| France | “9” | “26” | “22” | “26” | “16” | “107” |
| Germany | “3” | “3” | “35” | “54” | “5” | “37” |
| Czech Republic | “6” | “17” | “24” | “37” | “17” | “54” |
| UK | “5” | “6” | “39” | “32” | “19” | “132” |
| European countries | “—” | “11” | “31” | “31” | “27” | “145” |

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.2.1-9"></a>

###### Regional variation in the early infantile form

> “Two features emerge from the compiled data presented in Table 1: the early infantile neurological onset form appears more frequent in Southern Europe and the Middle East, and patients with the adult‐onset neurological form seem to represent at least 20% of the cases of NPC and, owing to their longer survival, probably constitute the largest patient group in terms of disease prevalence”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.2.1-10"></a>

###### Distribution by age at neurological onset: International Niemann-Pick Disease Registry

> “A total of 203 NPC patients from six European countries were included in this study.”
> “Among enrolled patients, 168 had known neurological manifestations: 43 (24.2%) had early-infantile onset, 47 (26.4%) had late-infantile onset, 41 (23.0%) had juvenile onset, and 37 (20.8%) had adult onset.”
> “10 (5.6%) patients had the neonatal rapidly fatal systemic form.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.2.1-11"></a>

###### Distribution by age at neurological onset: pooled national cohorts and NPC Registry

> “Data for 789 patients from five large national cohorts and from the NPC Registry were collected and combined.”
> “The Neurological onset group comprised 97 early infantile, 210 late infantile, 198 juvenile, and 163 adolescent/adult patients (Table 1).”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.1.2.1-12"></a>

###### Distribution by age at neurological onset: NPC Registry at closure

> “At database closure, 472 patients from 22 countries were enrolled in the NPC Registry (see Additional file 1), with a similar proportion of males (n = 245; 51.9%) and females (n = 227; 48.1%).”
> “Patients with known age at onset of neurological symptoms (n = 422) were categorized as early-infantile (n = 57; 13.5%), late-infantile (n = 108; 25.6%), juvenile, (n = 134; 31.8%), or adolescent/adult (n = 123; 29.1%) onset (Table 2).”

Source: [Patterson et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7183679/)

<a id="topic-2.2.1.2.1-13"></a>

###### Early infantile neurological onset among patients diagnosed in France, 1990 to 2013

> “During the period 1990–2013, a total of 153 new patients with NP-C (from perinatal period to adulthood) were diagnosed in France, among which 32 patients (21%) with neurological onset before 2 years of age, who were thus classified as suffering from the EI neurological form of the disease.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Niemann-Pick disease type C

<a id="topic-2.2.1.2.2-1"></a>

###### United States diagnosed and estimated prevalence from claims data

> “A total of 308 million unique individuals were represented in the database.”
> “Of these, 294 individuals had an NPC diagnosis, yielding an identified NPC prevalence of 0.95 per million people in the United States.”
> “305 individuals were diagnosed with NPC and/or were treated with miglustat without having a diagnosis for either Gaucher or GM1 gangliosidosis, yielding an NPC diagnosed or treated prevalence of 0.99 per million people in the United States.”
> “Applying this number to the distribution of NPC type (based on age of neurologic symptom onset) and corresponding mortality estimates generates an estimated 943 prevalent cases of NPC, or 2.9 cases of NPC per million people in the United States.”

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States claims analysis: data source, methods, and author affiliations

> “For the first two objectives, patients were identified using the Symphony Integrated DataVerse database (Oct 2015-Jan 2020).”
> “For the third objective, published NPC incidence (1 per 89,000 live births) and expected mortality estimates were applied to the 2018 United States birth rate (11.6 per 1000) and population size (326.7 million).”
> “Blair Orr, Shilpa Chatlani, Kwangchae Yoon, and Dan Gallo are shareholders and employees of Orphazyme USA Inc.”

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)

<a id="topic-2.2.1.2.2-3"></a>

###### Infantile-onset share of United States prevalent cases: sponsor statement

> “In the U.S., approximately half of those living with NPC – 475 children – have infantile-onset NPC”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.1.2.2-4"></a>

###### Undiagnosed fraction in the United States: sponsor statement

> “In the U.S., approximately two-thirds of people with Niemann-Pick disease, type C (NPC) remain undiagnosed”
> “Genetic testing is required to confirm the diagnosis of NPC but is often delayed due to diffuse symptoms that overlap with multiple neurological conditions as well as low disease awareness among healthcare providers.”

Source: [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)

<a id="topic-2.2.1.2.2-5"></a>

###### FDA statement of disease frequency

> “Niemann-Pick disease type C (NPC) is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which the body cannot properly process cholesterol and other fats inside cells.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.2.1.2.2-6"></a>

###### Prevalence estimates in Western Europe and the United States

> “The prevalence of NPC has been estimated at 1:150,000 in Western Europe.”
> “The prevalence of NPC in the United States was estimated at 2.9 in one million, based on assumption of underdiagnosis and misdiagnosis”
> “The prevalence of NPC in childhood is probably underestimated, owing to the nonspecific presentations in that age group.”
> “The overall prevalence is likely higher than the calculated incidence, owing to relatively prolonged survival in those with later-onset disease, although no comprehensive data are available.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.2.2-7"></a>

###### Oregon Medicaid drug evaluation statement of frequency

> “Type C affects roughly 1 in 100,000 to 150,000 people, though it may be underrecognized.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.1.2.2-8"></a>

###### Share of adult-onset disease among prevalent cases

> “Statement #8: Adult‐onset NPC patients may represent up to a third of all NPC patients.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.2.2-9"></a>

###### Diagnosed cases in Australia

> “In the absence of a national register, the number of current diagnosed cases in Australia is estimated by clinical services as between 25 and 33, although this is widely considered an underestimate, with many cases likely undetermined or in some cases misdiagnosed.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Life expectancy by age at neurological onset

> “Life expectancy among patients with NPC disease varies depending on the age at neurological symptom onset, ranging from a few days to many decades”
> “Data from a large cohort of French NPC patients and the INPDR indicate that the age at onset of neurological symptoms predicts disease severity and life expectancy”
> “The acute pre/perinatal form (fetal hydrops or ascites, early liver, multi‐organ failure, and in some cases, respiratory failure), which usually results in death before the age of 6 months.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.3-2"></a>

###### FDA statement on infantile-onset disease severity

> “Patients whose neurological symptoms begin before age 6 face the most serious form of the disease.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.2.1.3-3"></a>

###### Mean ages of death in infantile onset: sponsor statement

> “Earlier neurological onset is associated with more rapid disease progression and earlier mortality with mean ages of death of ~5.6 years for early infantile-onset (age of neurological onset <2 years) and ~13.4 years for late-infantile onset (2 to <6 years).”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.1.3-4"></a>

###### Mean age of death by onset category in a United Kingdom cohort, and survival after diagnosis

> “Imrie, et al. [6] published a report of 74 patients in a United Kingdom cohort.”
> “In the neonatal onset group the mean age of death (± SD) was 0.19 ± 0.22 years, in the early-infantile group mean age of death was 5.6 ± 2 years, in the late infantile group the mean age of death was 13.4 ± 6.7, and in the juvenile onset group the mean age of death was noted to be 25.9 ± 8.9 years.”
> “The adolescent /adult group had a mean age of death of 33.7 ± 6.2 years.”
> “Fifty percent of NPC patients with neurological onset either prior to 2 years or between 2-11 years of age died within approximately 3 or 7 years of diagnosis.”

Source: [Bianconi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6535124/)

<a id="topic-2.2.1.3-5"></a>

###### Age at death across all onset categories: 338 deceased individuals

> “Median age of death for this cohort was 13 years.”
> “The histograms clearly show a marked increase in deaths starting at 4 years of age.”
> “Median ages of death for these four-time intervals were 5, 12, 13, 14 years, respectively.”
> “Except for the first time period, where the number of subjects was very low, there did not appear to be a significant increase in survival from 1998 to 2018.”

Source: [Bianconi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6535124/)

<a id="topic-2.2.1.3-6"></a>

###### Median ages at diagnosis and death by onset category: International Niemann-Pick Disease Registry

> “Data on the age at diagnosis and age at death was available for 59 patients.”
> “In patients with the early infantile form (N = 17), the median ages at diagnosis and death were 1.8 years (0.3–17.0) and 5 years (0.8–22.0), respectively.”
> “In patients with the late infantile form (N = 17), the median ages at diagnosis and death were 4.4 years (0.1–8.8) and 8.8 years (5.0–16.0) respectively.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.3-7"></a>

###### Untreated early infantile onset in France: median survival

> “In the untreated group, the median survival was 4.42 years, with an age at death comprised between 3.1 and 6.5 years for 12 patients; 4 patients were unfortunately lost to follow-up when aged 2.9 to 3.3 years.”
> “No patient was alive beyond the age of 7 years 5 months in either group.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.3-8"></a>

###### Crude death rates during periods without miglustat, by onset category

| Age at neurological onset, Neurological onset group | Patients in the analysis, n | Total patient-years | Death rate (per 100 patient-years) | Patients who died, n (%) |
| --- | --- | --- | --- | --- |
| All ages | “406” | “3174.8” | “5.61” | “178 (43.8)” |
| Early infantile (<2 years) | “65” | “226.3” | “11.93” | “27 (41.5)” |
| Late infantile (2 to <6 years) | “139” | “1016.6” | “7.87” | “80 (57.6)” |
| Juvenile (6 to <15 years) | “111” | “1035.8” | “4.54” | “47 (42.3)” |
| Adolescent/adult (≥15 years) | “91” | “896.2” | “2.68” | “24 (26.4)” |

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.1.3-9"></a>

###### Survival by onset category in registry-based analyses

> “The age of neurological manifestation onset has been recognised as a predictor for severity, rate of disease progression, and life expectancy.”
> “Survival appears to be the poorest in patients with rapidly progressive early infantile neurological onset, whereas patients with more slowly progressive adult onset NP‐C tend to live longer.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.1.3-10"></a>

###### Course of the early infantile and late infantile forms

> “Delay of developmental motor milestones from the age of 8-9 months and central hypotonia constitute the first neurologic symptoms, which become evident between the age of 1 and 2 years.”
> “Many of these children never learn to walk.”
> “Survival rarely exceeds 5 years.”
> “The child often presents with gait problems, frequent falls and clumsiness between 3 and 5 years of age, due to ataxia.”
> “Death most often occurs between 7 to 12 years in this form.”
> “Similarly, the lifespan of the patients varies between a few days until over 60 years of age, although a majority of cases die between 10 and 25 years of age”

Source: [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)

<a id="topic-2.2.1.3-11"></a>

###### Lifespan by phenotypic form: Oregon Medicaid drug evaluation

> “The fetal and early infantile form often presents with fetal hydrops and ascites and is usually fatal within 5 years.”
> “The late infantile form usually presents with seizures and other neurological manifestations; lifespan is generally 7 to 12 years.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.1.3-12"></a>

###### United States National Niemann-Pick C1 disease database: ages at diagnosis and death

> “The present study provides basic clinical and health information from the National Niemann-Pick C1 disease database that was obtained using a clinical questionnaire of 83 questions mailed to families affected by NPC1 disease living in the United States.”
> “The average age of diagnosis for NPC1 disease was 10.4 years, with one-half of patients being diagnosed before the age of 6.9 years.”
> “The average age of death for NPC1 disease was 16.2 years, with one-half of patients dying before the age of 12.5 years.”

Source: [Garver et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17497724/)

<a id="topic-2.2.1.3-13"></a>

###### Age range of death across the disease spectrum

> “Niemann-Pick Disease Type C (NPC) is an ultra-rare progressive neurodegenerative disease caused by autosomal recessive mutations in the NPC1 or NPC2 genes that lead to premature death, with most individuals dying between 10 and 25 years of age.”

Source: [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)

<a id="topic-2.2.1.3-14"></a>

###### Cause of death: aspiration pneumonia and bronchopneumonia

> “Death from aspiration pneumonia usually occurs in the late second or third decade”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

> “The most common cause of death in individuals with neurological symptoms is aspiration pneumonia preceded by dysphagia”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

> “Epidemiological data suggest that bronchopneumonia subsequent to food or fluid aspiration is a major cause of mortality in NP-C and other neurodegenerative disorders.”
> “While precise causes of death are not consistently reported in NP-C, two studies have identified bronchopneumonia as the leading cause of death in two separate NP-C patient cohorts, accounting for approximately two-thirds of patients”

Source: [Walterfang et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3552828/)

<a id="topic-2.2.1.3-15"></a>

###### Rate of neurological progression in a prospective observational cohort

> “Of the 36 individuals with NPC (2–18 years) enrolled, 31 (86.1%) completed the 6–14-month observation period; 30/36 (83.3%) were receiving miglustat as part of routine clinical care.”
> “The mean (± SD) increase in the total 5-domain NPCCSS was 1.4 (± 2.9), representing a mean (± SD) change per 6 months of 0.75 (± 1.58; annualized progression = 1.5 points) (Fig. 3a).”

Source: [Mengel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7684888/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### NPC1 and NPC2 proteins in lysosomal cholesterol trafficking

> “These proteins work sequentially to facilitate the bidirectional cellular trafficking of cholesterol and other lipids from the lysosome to the endoplasmic reticulum”
> “Variants that cause disease in either gene lead to tissue accumulation of multiple lipids”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.4-2"></a>

###### Functions of the NPC1 and NPC2 proteins

> “NPC1 is an integral membrane protein that facilitates the transport of cholesterol across the endolysosomal membrane, and NPC2 is a non-enzymatic soluble lysosomal protein that likely transports cholesterol from the lysosomal lumen to NPC1”
> “Impaired function of either NPC1 or NPC2 leads to an endolysosomal accumulation of cholesterol and glycosphingolipids”

Source: [Bianconi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6535124/)

<a id="topic-2.2.1.4-3"></a>

###### Molecular pathogenesis: loss of function and lysosomal lipid accumulation

> “Pathogenic variants described throughout NPC1 and NPC2 lead to either dysfunction or complete loss of the proteins NPC1 or NPC2, the deficiency of which leads to accumulation in the lysosomes of multiple lipid cargoes including unesterified cholesterol, glucosylceramide, and gangliosides.”
> “The consequent lysosomal dysfunction leads to a cascade of downstream effects, including an inflammatory response and triggering of apoptosis.”
> “Mechanism of disease causation. Loss of function; supported by in vitro studies”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.4-4"></a>

###### Cellular hallmark and its reversal by 2-hydroxypropyl-beta-cyclodextrin in cultured cells

> “In Niemann-Pick C disease cells (either NPC1 or NPC2), the cholesterol does not exit the endocytic pathway but accumulates within lysosomes.”
> “This anomaly constitutes the cellular hallmark of the disease.”
> “Very recently, it was further shown that the block in cholesterol delivery to the ER can also be overcome by 2-hydroxypropyl-beta-cyclodextrin”

Source: [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)

<a id="topic-2.2.1.4-5"></a>

###### Neuronal pathogenesis

> “The pathogenesis of the neuronal dysfunction appears by far more complex, since brain cholesterol is synthesized locally, mostly by oligodendroglial cells and to a lesser extent by astrocytes and neurons.”
> “Nevertheless, since abnormal filipin staining of neurons is also observed in a wide spectrum of other lysosomal storage disorders [discussed in 63], the exact participation of cellular cholesterol transport abnormalities in the pathophysiology of the neurodegenerative NP-C disease remains elusive.”

Source: [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)

<a id="topic-2.2.1.4-6"></a>

###### Genotype and early-onset disease

> “Premature-termination-codon variants, variants involving the sterol-sensing domain, and p.Ala1054Thr in the cysteine-rich luminal loop of NPC1 are associated with early-infantile NPC”
> “No individuals with p.Ile1061Thr had early-infantile NPC in an international study that included the Hispanic population in the upper Rio Grande Valley of the southwestern United States, as well as the United Kingdom and France”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.4-7"></a>

###### Cholesterol trafficking defect and genotype: Oregon Medicaid drug evaluation

> “Presence of stop mutations on both alleles is associated with severe disease progression and early onset, while other genotype/phenotype relationships have not been consistently described.”
> “These mutations result in abnormal cholesterol trafficking and esterification.”
> “Toxic cholesterol accumulates in the lysosome and results in cell damage.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Guideline statements on suspicion, biomarker screening, and genetic confirmation

> “Statement #9: The signs and symptoms of NPC are nonspecific, which may lead to misdiagnosis.”
> “However, the presence of cataplexy and/or saccadic eye movement abnormalities should raise suspicion of NPC and help differentiate NPC from other neurodegenerative disorders.”
> “Statement #12: Biomarker assessment should be considered the first‐line test to screen for NPC.”
> “Three classes of biochemical markers are currently in use (oxysterols, PPCS, and lyso‐SM) or development (bile acid derivatives).”
> “Typically, the diagnosis must be confirmed by deoxyribonucleic acid (DNA) sequencing, although diagnostic routes depend on tool availability.”
> “Statement #13: Any individual whose diagnosis of NPC is considered based on their clinical manifestation and/or abnormal biomarker profile should undergo genetic testing for NPC genes to confirm the diagnosis.”
> “Referral to a clinical geneticist or genetic counselor should be considered following NPC diagnosis.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-2"></a>

###### Biomarkers: oxysterols, PPCS and lyso-SM, and bile acids

> “The oxysterols cholestane‐3β, 5α, 6β‐triol (C‐triol) and 7‐ketocholesterol (7‐KC) are sensitive markers of NPC, though C‐triol is more specific”
> “Striking elevations of PPCS have been reported in both NPC and ASMD, with high sensitivity for detecting both disorders but poor distinction between them.”
> “A high PPCS/lyso‐SM ratio appears to be very specific to NPC.”
> “It is highly sensitive and more specific than oxysterols (only elevated in ASMD and NPC).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-3"></a>

###### Genetic testing: variant spectrum and limits of routine sequencing

> “Genetic testing (NPC1 and NPC2) is recommended to confirm NPC diagnosis”
> “However, some genetic changes (e.g., deep intronic variants, complex structural variants) may not be identified by routine sequencing methods and require complementary testing”
> “The identification of two alleles with known disease‐causing variants in either the NPC1 or NPC2 gene confirms the diagnosis of NPC.”
> “To date, about 700 different NPC1 variants have been reported, among which around 420 are considered pathogenic, with only a limited number of common or recurrent (often in certain populations) variants”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-4"></a>

###### Suspicion Index screening tools

> “The Niemann‐Pick disease type C Suspicion Index (NPC‐SI) has been developed as a simple, interactive screening tool to assist HCPs in the early identification and referral of individuals suspected of NPC”
> “The NPC‐SI includes two age‐specific screening tools: one for individuals older than 4 years and another for individuals younger than four (early‐onset NPC).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-5"></a>

###### Early-onset Suspicion Index for children aged 4 years or younger

> “An early-onset NP-C SI was constructed following retrospective chart review of symptom presentation in 200 patients from nine centres comprised of 106 NP-C cases, 31 non-cases and 63 controls.”
> “Visceral symptoms were amongst the strongest predictors.”
> “Except for gelastic cataplexy and vertical supranuclear gaze palsy, central nervous system symptoms were not discriminatory in this population.”
> “The early-onset NP-C SI can help physicians, especially those with limited knowledge of NP-C, to identify patients aged ≤4 years who warrant further investigation for NP-C.”

Source: [Pineda et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4957867/)

<a id="topic-2.2.1.5-6"></a>

###### Clinical findings by age group and first-line laboratory tests

> “Early infantile (age <2 years). Fetal ascites or neonatal liver disease, particularly when the latter is accompanied by prolonged cholestatic jaundice and pulmonary infiltrates.”
> “Late infantile (ages 2 to <6 years). Often presents with hypotonia and developmental delay.”
> “Note: The absence of organomegaly never eliminates the diagnosis of NPC.”
> “Assay of oxysterols has largely replaced formerly used methods of diagnosis and is now regarded as both a robust screening test and a first-line diagnostic test for NPC”
> “Bile acids derived from 7-oxocholesterol and from cholestane-3β,5α,6β-triol are also elevated in NPC, and may be useful diagnostic markers in neonates in whom oxysterols may be less reliable, as well as in older individuals”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.5-7"></a>

###### Molecular testing approaches

> “Molecular genetic testing approaches can include a combination of comprehensive genomic testing (exome sequencing, genome sequencing) and gene-targeted testing (multigene panel).”
> “Note: Single-gene testing (sequence analysis of NPC1 and/or NPC2, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.”
> “Exome sequencing is most commonly used; genome sequencing is also possible.”
> “(2) Identification of NPC1 or NPC2 variants of uncertain significance does not establish or rule out the diagnosis.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.5-8"></a>

###### Neonatal cholestasis as a presentation of NPC

> “A study from Colorado found that 27% of infants initially diagnosed with idiopathic neonatal cholestasis (see Pediatric Genetic Cholestatic Liver Disease Overview) and 8% of all infants with cholestasis had NPC”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.5-9"></a>

###### PPCS biomarker performance

> “Blood‐based biomarkers have replaced filipin staining.”
> “PPCS‐based assays now offer 100% sensitivity, 96.6% specificity in identifying NP‐C1 cases from controls and NP‐C1 carriers.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.5-10"></a>

###### Diagnostic delay by age at neurological onset: NPC Registry

> “A diagnostic delay was apparent in each of these age at neurological onset categories, with a mean delay between the appearance of first neurological symptoms and a confirmed diagnosis of NP-C of 2.5 years in early-infantile, 4.3 years in late-infantile, 6.2 years in juvenile, and 6.3 years in adolescent/adult patients (Table 2).”

Source: [Patterson et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7183679/)

<a id="topic-2.2.1.5-11"></a>

###### Diagnostic delay in pooled cohorts

> “Non‐specific clinical presentation of NP‐C often prevents timely diagnosis, which has been shown to be delayed by a mean of 4.1 years from the onset of neurological manifestations.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.1.5-12"></a>

###### Mean age at diagnosis: International Niemann-Pick Disease Registry

> “The mean (SD) age at diagnosis was 11.2 (14.2) years.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.5-13"></a>

###### Diagnostic challenges and consequences

> “Challenges also remain in differential diagnosis, prolonged times to diagnosis, and in some cases, misdiagnosis”
> “Consequently, NPC patients may encounter delayed or restricted access to suitable management strategies.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-14"></a>

###### Sponsor diagnostic program: Test for NPC and NPC GenomeComplete

> “Designed to shorten the diagnostic journey and help identify children with NPC who might otherwise never be diagnosed, the program includes NPC GenomeComplete, a Beren-sponsored genetic testing program, performed by GeneDx, that offers no-charge whole-genome sequencing, family testing, and post-test genetic counseling for eligible patients.”
> “According to the NPC Registry, it takes 2.5-4.3 years after a child’s first neurological symptom to diagnose them with I-NPC.”
> “Eligibility is through any of three pathways: clinical findings consistent with NPC, an elevated NPC biomarker, or a confirmed family history of NPC.”
> “An expedited pathway for patients requiring urgent medical decisions, returning preliminary results in approximately 48 hours for children in rapid neurological decline, against a standard turnaround of approximately four weeks”
> “Genome sequencing, which covers both coding and non-coding regions of NPC1 and NPC2”

Source: [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)

<a id="topic-2.2.1.5-15"></a>

###### Newborn screening: status and bile acid dried blood spot assay

> “Newborn screening has the potential to enable earlier diagnosis prior to the onset of neurological symptoms.”
> “NP‐C is not currently included in the Australian newborn screening programmes.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

> “A high-throughput, mass spectrometry-based method was developed and validated to measure the glycine-conjugated bile acid in dried blood spots.”
> “Analysis of dried blood spots from 4992 controls, 134 NPC carriers, and 44 NPC subjects provided 100% sensitivity and specificity in the study samples.”

Source: [Jiang et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5316294/)

> “To address this critical question, we obtained the newborn DBS for already diagnosed NPC1 subjects (n=15) and carriers (n=3) residing in California, New York, and Michigan, states that archive residual DBS in biorepositories.”
> “Bile acid B, the more specific biomarker for which the fully validated DBS assay was developed, was detected in 8/15 NPC1 patients, and elevated above the cut-off in 2/15 patients (the two samples with the shortest storage time).”
> “These results demonstrate that newborn screening for NPC1 disease is feasible using bile acid biomarkers.”

Source: [Jiang et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6365165/)

<a id="topic-2.2.1.5-16"></a>

###### New York pilot newborn screening study listing NPC among its conditions

| Field | Quoted record |
| --- | --- |
| Brief summary | “ScreenPlus is a consented, multi-disorder pilot newborn screening program implemented in conjunction with the New York State Newborn Screening Program that provides families the option to have their newborn(s) screened for a panel of additional conditions.” |
| Enrollment target | “Over a nine-year period, ScreenPlus aims to screen 100,000 infants born in eight high birthrate hospitals in New York for a flexible panel of rare genetic disorders.” |
| Condition | “Niemann-Pick Disease, Type C” |

Source: [ClinicalTrials.gov NCT05368038](https://clinicaltrials.gov/study/NCT05368038)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Age-dependent presentation: visceral in infancy, neurological from late infancy onward

> “Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent.”
> “The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, cholestatic jaundice, and (in some instances) pulmonary infiltrates.”
> “From late infancy onward, the presentation is dominated by neurologic manifestations.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-2"></a>

###### Hepatic and visceral symptoms: neonatal cholestasis and hepatosplenomegaly in the pre/perinatal period

> “Statement #4: NPC primarily manifests in the pre/perinatal age group as liver disease presenting with prolonged cholestatic jaundice, hepatosplenomegaly, and in some cases fetal hydrops or ascites and acute liver failure, with or without pulmonary disease.”
> “In most cases, jaundice resolves spontaneously by 3–4 months of age, while organomegaly persists to variable degrees.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-3"></a>

###### Hepatic and visceral symptoms: frequency of splenomegaly, hepatomegaly, and neonatal jaundice in the International Niemann-Pick Disease Registry

> “Here we report NPC patient data from the International Niemann-Pick Disease Registry (INPDR).”
> “The proportion of patients who developed splenomegaly was 72.8%, whilst hepatomegaly was reported in 39.5% of patients.”
> “Similarly, neonatal jaundice was noted in 39.5% of patients, and hepatic failure in the neonatal period was 6.2%.”
> “The proportion of patients with neonatal jaundice, spleno- and hepatomegaly decreased with increasing age of neurological onset.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.6-4"></a>

###### Hepatic and visceral symptoms: neonatal liver disease and earlier neurological onset in 93 individuals with NPC1

> “Liver disease was characterized in 93 individuals with NPC1 using FibroScan, abdominal ultrasound, and plasma liver function tests at baseline and longitudinally over up to a four-year period.”
> “Those with no history of neonatal liver disease had an average age of 10.3 years at time of neurological symptoms, compared to 5.9 years for those with mild/moderate disease and 3.6 years for those with severe disease (p = 0.002).”

Source: [Agrawal et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12818573/)

<a id="topic-2.2.1.6-5"></a>

###### Respiratory symptoms: pulmonary foam-cell infiltration in infancy

> “Infiltration of the lungs with foam cells may accompany neonatal liver disease or occur as a primary presenting feature (pulmonary failure secondary to impaired gas exchange).”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-6"></a>

###### Motor and developmental symptoms: hypotonia and delayed motor milestones in early infantile onset

> “Statement #5: Hypotonia and delay in developmental motor milestones characterize the neurological manifestation of NPC in early infancy. Hepatosplenomegaly and/or prolonged neonatal jaundice are almost invariably noted, although cases with severe hypotonia in early infancy without obvious visceral disease can occur. Pulmonary disease may also be present.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-7"></a>

###### Motor and developmental symptoms: early infantile onset in a French cohort

> “Data available on all NP-C patients with early infantile neurological onset diagnosed in France between 1990 and 2013 were compiled.”
> “All patients in the present EI-NP-C series began neurological symptoms before 18 months of age”
> “only few patients temporarily acquired autonomous walking, and none did acquire a fully normal gait.”
> “Hypotonia and motor development delay were the first neurological sign in 85% of the patients, ataxia, and psychomotor regression in the remaining 15%.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.6-8"></a>

###### Motor and developmental symptoms: clumsiness, gait disturbance, and speech delay in late infantile onset

> “Statement #6: Clumsiness, gait disturbance, and fine motor skill impairments characterize this age of disease onset. Speech delay, a history of neonatal cholestasis, seizures, pulmonary disease, variable visceromegaly, and failure to reach or loss of developmental milestones may be noted.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-9"></a>

###### Motor and developmental symptoms: developmental milestone delay by age at neurological onset in the registry

> “Of the 46 patients where data is available, the most common manifestations were delay/impairments in: cognition (69.6%), speech (60.9%), motor (60.9%) and social (45.7%).”
> “In respect to neurological classification, speech delay was most common in early infantile (91.7%), whilst cognitive impairment was most common in late infantile (78.9%) and adult (100%), with motor delay (33.3%) and cognitive impairment (33.3%) predominant in juvenile onset.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.6-10"></a>

###### Neurological symptoms: frequency of neurological manifestations in the registry

> “The most common neurological manifestations reported include cognitive impairment (78.5%), dysarthria (75.9%), ataxia (75.9%), vertical supranuclear gaze palsy (VSGP) (70.9%), dysphagia (69.6%), dystonia (53.2%), seizures (48.1%), and cataplexy (35.4%).”
> “Overall, the late infantile onset subgroup made up the highest proportion of neurological manifestations, with the exception of psychiatric manifestations and cognitive impairment.”
> “The least prevalent neurological manifestations were psychiatric manifestations (13.9%) and hearing impairment (7.6%).”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.6-11"></a>

###### Oculomotor symptoms: vertical supranuclear saccadic palsy and gaze palsy

> “Vertical supranuclear saccadic palsy (VSSP), followed later by vertical supranuclear gaze palsy (VSGP), is typically present but often unrecognized.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

> “Children compensate for the oculomotor deficits with blinks and head / upper body movements that represent a diagnostic clue for this disease.”
> “VSSP first manifests as decreased velocity of vertical saccades, gradually slowing down and eventually lost, resulting in restricted range of vertical eye movements, or VSGP.”
> “In late stages of the illness, horizontal saccades are also impaired.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-12"></a>

###### Seizures and gelastic cataplexy

> “Approximately one third of individuals with NPC have partial and/or generalized seizures.”
> “Epilepsy may be refractory to medical therapy in some.”
> “About 20% of children with NPC have gelastic cataplexy, a sudden loss of muscle tone evoked by a strong emotional (humorous) stimulus.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-13"></a>

###### Seizures and gelastic cataplexy: early infantile onset

> “During the later course of disease, about half of the patients developed seizures, and approximately one fourth gelastic cataplexy.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.6-14"></a>

###### Movement disorder and bulbar symptoms: dystonia, dysarthria, and dysphagia

> “In addition to the manifestations above, many children develop dystonia, typically beginning as action dystonia in one limb that gradually spreads to involve all limbs and axial muscles.”
> “Speech gradually deteriorates, with a mixed dysarthria and dysphonia.”
> “Dysphagia progresses in parallel with the dysarthria, and oral feeding eventually becomes impossible.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-15"></a>

###### Auditory symptoms: hearing loss in 50 patients with NPC1

> “Data from 50 patients with NPC1 confirm a prevalent, often high frequency, hearing loss that is progressive in at least some individuals.”
> “Retrocochlear involvement is common, and some patients present with a profile of auditory neuropathy spectrum disorder.”
> “Moreover, of the 31 patients with behavioral data, 23 (74%) presented with clinically significant hearing loss involving the frequencies most important to speech understanding (500–4000 Hz).”

Source: [King et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3895917/)

<a id="topic-2.2.1.6-16"></a>

###### Auditory symptoms: sensory deafness as a first symptom in late infantile onset

> “The first symptoms may be gelastic cataplexy (sometimes associated with narcolepsy) or sensory deafness.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.6-17"></a>

###### Cognitive symptoms: progressive cognitive impairment in childhood

> “These physical manifestations are accompanied by insidiously progressive cognitive impairment, often mistaken at first for simple learning disability.”
> “As the disease progresses, it becomes clear that the child is mentally deteriorating.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.6-18"></a>

###### Cognitive and psychiatric symptoms: juvenile and adult onset

> “Statement #7: Juvenile onset manifests as cognitive impairment (lagging behind peers in school, language and learning difficulties), coordination problems (clumsiness, frequent falls, progressive ataxia, and dystonia), seizures, and VSGP.”
> “Cognitive impairment invariably occurs and tends to present with higher rates of psychiatric illness alongside neurological manifestations.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Dysphagia and nutritional support in early infantile onset

> “Many data were missing in the later follow-up of patients (Table 3) but by order of frequency, neurological manifestations included: swallowing troubles (18 patients, 16 of whom required enteral feeding by nasogastric tube or gastrostomy, all before 3 years of age), limb hypertonia (18 patients), cerebellar signs (16 patients), VSGP (14 patients), seizures (12 patients), neuropathic pain (9 patients), gelastic cataplexy (7 patients).”
> “As for later onset NP-C forms, swallowing troubles were very frequent in EI-NP-C patients, with a need of nutritional support for 88% of untreated patients and 100% of miglustat treated patients, at a similar median age of 2.75 and 2.92 years respectively.”
> “Lower limbs were more severely involved than upper limbs, and medications were poorly efficient using antispastic, antidystonic and antalgic drugs in more than 75% of patients.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

<a id="topic-2.2.1.7-2"></a>

###### Dysphagia and aspiration across the disease course

> “Dysphagia occurs in most NP-C patients at some point in the disease course, ranging in severity from occasional swallowing difficulties to loss of swallowing function necessitating placement of a nasogastric tube or gastrostomy feeding”

Source: [Walterfang et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3552828/)

<a id="topic-2.2.1.7-3"></a>

###### Silent aspiration in the NIH NPC1 natural history study

> “We aimed to characterize aspiration and silent aspiration in the National Institutes of Health (NIH) NPC1 Natural History Study (NCT00344331).”
> “Silent aspiration occurred in 24/130 (18.4%) participants.”
> “Considering aspiration risk, 27/130 (20.8%) had NIH-PAS > 1, including all silent aspirators.”
> “Mean time to silent aspiration was ~ 10 years from neurologic symptom onset, with no difference by neurological disease onset.”
> “Silent aspiration is common in NPC1 and closely linked to advancing neurologic disease severity than to age-of-onset phenotype.”

Source: [Solomon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13539892/)

<a id="topic-2.2.1.7-4"></a>

###### Functional disability by domain in the registry

> “A 6-domain composite disability scale was used to calculate the overall disability score for each neurological form.”
> “Across all with neurological onset, the majority of patients showed moderate to severe impairments in all domains, except for ‘swallowing’ and ‘seizure’.”
> “The composite disability scores were notably higher in patients with early onset neurological signs, particularly in late infantile patients.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.7-5"></a>

###### Chronic liver disease, fibrosis, and hepatocellular carcinoma after neonatal liver disease

> “Higher liver stiffness measurement scores, suggesting increased risk for liver fibrosis, were associated with a history of significant liver disease in infancy (p = 0.001).”
> “In addition, individuals who had severe liver disease at birth are at higher risk for developing clinically significant liver disease after the neonatal period.”
> “Given multiple reports of hepatocellular carcinoma in individuals with NPC1, those with a history of severe liver disease should be closely monitored.”

Source: [Agrawal et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12818573/)

<a id="topic-2.2.1.7-6"></a>

###### Gastrointestinal, liver, and other comorbidities in the 2025 guideline

> “NPC has the highest early onset penetrance of Crohn's among monogenic diseases due to patients' predisposition to intestinal inflammation.”
> “Although rare in childhood, patients with NPC might have an increased risk of hepatocellular carcinoma (HCC).”
> “Individuals with NPC are at increased risk of hypersalivation/drooling.”
> “There is an increased prevalence of behavioral problems and other psychiatric disorders, such as anxiety, depression, or psychosis, in NPC.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.7-7"></a>

###### Progressive dementia and death from aspiration pneumonia in childhood-onset disease

> “Although cognitive impairment may be subtle at first, it eventually becomes apparent that affected individuals have progressive dementia.”
> “Seizures usually improve if the child's survival is prolonged; this improvement presumably reflects continued neuronal loss.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Niemann-Pick disease type C

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Effects on wellbeing and quality of life in the 2025 guideline

> “As a progressive disease, these challenges translate to worse clinical outcomes, adverse effects on individuals' overall wellbeing and quality of life (QoL), and reduced life expectancy”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.8.1-2"></a>

###### Survey and interviews of caregivers and adult patients in the United States and United Kingdom

> “A survey of caregivers for patients with NPC and adult patients with NPC (n = 49; patient age: 13 months–65 years) assessed NPC severity, importance of NPC symptoms, and how symptoms impacted patients’ and caregivers’ activities of daily living (ADLs) and health-related QOL (HRQOL).”
> “A total of 49 surveys were completed across two countries: 37 in the US and 12 in the United Kingdom (UK).”
> “Findings indicated that the most important manifestations of NPC were ambulation, swallowing, speech, fine motor skills, and cognition, which were those that had the most significant impact on ADLs and HRQOL.”
> “ADLs and HRQOL were impaired in the majority of patients as well as their caregivers.”
> “The findings were independent of current age, age of onset of symptoms, and level of NPC disease-related disability; however, the impact increased at higher levels of disease disability.”

Source: [Mengel et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8611877/)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient HRQOL domains affected, from the caregiver perspective

> “NPC and the impact it has upon ADLs also has a further effect upon patients’ HRQOL in a number of ways, with considerable impact on all major domains of HRQOL: emotional (n = 26; 92.9%), physical (n = 24; 85.7%), psychological (n = 10; 35.7%), and social (n = 22; 78.6%).”
> “Participants reported feelings of social isolation, loss of enjoyment in activities (patients), and feelings of sadness or worry (caregivers).”

Source: [Mengel et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8611877/)

<a id="topic-2.2.1.8.1-4"></a>

###### Caregiver HRQOL

> “The impact of NPC on caregivers’ HRQOL was reported by many participants (n = 15; 53.6%) as summarized in Table 7, which also presents example quotes to illustrate the impact.”
> “Emotional impacts were those most commonly reported by caregivers, who discussed feelings of sadness, worry, anxiety, or distress about the impacts NPC was having on the patient, and reported feeling they were always on alert, being concerned about the patient suffering an injury, illness, or deteriorating due to their NPC.”

Source: [Mengel et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8611877/)

<a id="topic-2.2.1.8.1-5"></a>

###### Focus groups with 19 patients and caregivers

> “To further grasp patient and caregiver perceptions and experiences with NPC, we carried out focus group discussions with pediatric and adult individuals with NPC (N = 19), with partial or full representation of the patient by their caregiver.”
> “Focus group discussions revealed that neurological signs, including declining cognition, memory loss, and psychiatric symptoms, as well as increasingly impaired mobility and motor function, are among the most pressing past and current concerns for patients and caregivers.”
> “Moreover, several participants also expressed concern over a loss of independence, social exclusion, and uncertainty for what the future holds.”

Source: [Golden et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10200045/)

<a id="topic-2.2.1.8.1-6"></a>

###### Disease-specific proxy-rated quality-of-life scales for children and adults

> “No scales currently exist to measure the impact of medication, physical therapy or clinical trials.”
> “NPC quality-of-life questionnaires for children (NPCQLQ-C) and adults (NPCQLQ-A) proxy prototype scales were produced and completed by 23 parents/carers of children (child age mean = 8.61 years) and 20 parents/carers of adults (adult age = 33.4 years).”
> “Reliability analysis resulted in a 15-item NPCQLQ-C and a 30-item NPCQLQ-A, which showed excellent internal consistency, Cronbach’s α = 0.925 and 0.947, respectively.”

Source: [Aston et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6803578/)

<a id="topic-2.2.1.8.1-7"></a>

###### Generic HRQOL instrument scores in eight Dutch adults

> “Eight patients with genetically confirmed NP-C were recruited from two Dutch University Medical Centers.”
> “All patients scored significantly lower on physical domains of HRQoL.”
> “The health related quality of life in our cohort, measured with the RAND-36, was on several domains significantly lowered compared to the general population”
> “Especially the general health perception was scored remarkably low, 35.0 on a scale of 0–100.”

Source: [Koens et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5007743/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Cost of illness in the United Kingdom, 2007 survey

> “In total, 18 Medical Resource Use questionnaires (29% response rate) were received and analysed.”
> “The mean total annual cost (SD) of NP-C per patient was 39,168 pounds (50,315 pounds); 46% were direct medical costs, to which home visits and residential care contributed 68% and 15%, respectively.”
> “If only direct medical costs were considered, the mean annual cost (SD) per patient was reduced to 18,012 pounds (46,536 pounds).”
> “The direct annual per-patient cost of NP-C illness in 2007 appears moderate when compared with other rare and severely disabling diseases.”
> “However, cost estimates may be conservative, since findings are limited by a small sample size, low survey response rate and potential recall bias.”

Source: [Imrie et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19725798/)

<a id="topic-2.2.1.8.2-2"></a>

###### Targeted review of economic evidence across Niemann-Pick disease types

> “Niemann-Pick disease (NPD) is a rare, progressive disorder associated with substantial socioeconomic burden.”
> “Nine studies (2012-2026) from Canada, Portugal, the US, Brazil, the UK, and multinational settings were included.”
> “A Portuguese study reported substantial direct healthcare costs associated with management of NPD.”
> “In the US, 70.0% of patients were aged < 18 years, with respiratory disorders accounting for most hospitalizations and emergency visits.”
> “In Brazil, hospitalizations increased from 33.3% at diagnosis to 45.9% during follow-up.”

Source: [Sharma et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/economic-perspectives-on-niemann-pick-disease-a-targeted-review-of-economic-evidence)

<a id="topic-2.2.1.8.2-3"></a>

###### Medication use in the International Niemann-Pick Disease Registry

> “Miglustat use was recorded in 62.4% of patients and the most common symptomatic therapies used by patients were antiepileptics (32.9%), antidepressants (11.8%) and antacids (9.4%).”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.8.2-4"></a>

###### Prescription adjudication and rejection rates for approved Niemann-Pick disease type C therapies

> “Prescription adjudication data showed low fill rates within 30 days for these drugs among all payers (Figure 4.8).”
> “For Aqneursa, both commercial payers and Medicaid rejected approximately 80% of prescriptions.”
> “For Miplyffa, 55%-65% of prescriptions were rejected by commercial payers and Medicaid.”
> “Thus, lengthy delays due to the prior authorization process may contribute to the high rejection rate, as very few prescriptions for either Aqneursa or Miplyffa were filled on the first attempt.”

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

<a id="topic-2.2.1.8.2-5"></a>

###### U.S. claims-based cost and resource use study of Niemann-Pick disease type C

No evidence found.

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Niemann-Pick disease type C on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Direct non-medical and indirect costs borne by patients and families in the United Kingdom

> “Direct non-medical costs accounted for 24% of the average annual cost per patient, mainly due to specialist education, and indirect costs 30%.”
> “As demonstrated by this study, a substantial proportion of the cost is shifted from the healthcare system to the patient, family and non-medical providers.”

Source: [Imrie et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19725798/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver burden and changes in employment

> “Along with these impacts, there was an increased risk of experiencing dangerous or life-threatening situations leading to loss of patient independence and additional caregiver burden, often requiring changes in lifestyle such as giving up work.”
> “Of the 43 caregivers completing the survey, 40 were a parent of the patient, one sibling, one grandparent, and one aunt.”

Source: [Mengel et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8611877/)

<a id="topic-2.2.1.8.3-3"></a>

###### Health insurance, Medicaid waivers, and access burden in a U.S. survey

> “Of the 79 respondents who completed the survey, 67 participated in interviews.”
> “However, 61% of respondents were unaware of Medicaid waivers and did not avail of them.”
> “Overall, 50% of respondents with childhood onset NPC selected Medicaid/Medicare and private insurance; 35% utilized Medicaid waivers.”
> “The most frequently cited access burden was the process of obtaining medical care and services.”
> “Delays and denials in obtaining essential medication, equipment, and services contributed to disease progression.”
> “Caregivers faced burnout and often questioned the utility of their advocacy.”

Source: [Diaz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9438239/)

<a id="topic-2.2.1.8.3-4"></a>

###### Out-of-pocket costs and financial assistance in a U.S. survey

> “Most respondents (90%) did not have difficulty paying for their medical expenses; however, this may reflect lack of approved therapy or bias in the group that was studied.”
> “Often, respondents mentioned paying high co-pays for drugs, especially miglustat, which is used off-label and costs approximately $58,000 per month and may not be covered by waivers”
> “Most respondents did not use a health savings account (68%) or seek financial assistance from co-pay support programs (92%), reduced payment programs (97%), free drug programs (95%), or nonprofit organizations (94%).”

Source: [Diaz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9438239/)

<a id="topic-2.2.1.8.3-5"></a>

###### Out-of-pocket exposure for approved therapies under Medicare Part B

> “If billed under Part B, Medicare recipients are usually responsible for 20% of the cost”
> “However, this is likely not the only reason, as 100% of patients with Medicaid had $0 out-of-pocket costs but still around 20% of prescription claims to Medicaid were reversed.”

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

<a id="topic-2.2.1.8.3-6"></a>

###### Family and carer burden in the Australian standard of care

> “A formal diagnosis, once established, places a substantial burden on the whole family, the negative impact of which is far‐reaching.”
> “Effective and optimal patient outcomes necessitate access to specialist multidisciplinary team (MDT) care, placing considerable societal, administrative and financial burden on the individual diagnosed with NP‐C, their family and carers.”
> “The burden of care coordination places significant strain on the carer.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.8.3-7"></a>

###### Public education and disability services for affected children in the United States

> “Developmental Disabilities Administration (DDA) enrollment is recommended.”
> “DDA is a US public agency that provides services and support to qualified individuals.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Medicare payment for NPC1 and NPC2 gene sequencing, 2026

> “2026,81406,,20260101,N,00282.88,Mopath procedure level 7”
> “npc1 (niemann-pick disease, type c1) (eg, niemann-pick disease), full gene sequence”
> “2026,81404,,20260101,N,00274.83,Mopath procedure level 5”
> “npc2 (niemann-pick disease, type c2 [epididymal secretory protein e1]) (eg, niemann-pick disease type c2), full gene sequence”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="topic-2.2.1.8.4-2"></a>

###### Medicare payment for exome and genome sequencing, 2026

> “2026,81415,,20260101,N,04780.00,Exome sequence analysis”
> “Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis”
> “2026,81425,,20260101,N,05031.20,Genome sequence analysis”
> “Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="topic-2.2.1.8.4-3"></a>

###### Cost-effectiveness of plasma oxysterol screening in intellectually disabled patients in Canada

> “Our objective is to compare costs and outcomes of plasma oxysterol screening versus current practice in diagnosis of NP-C disease among intellectually disabled (ID) patients using decision-analytic methods.”
> “The outcomes of the base case model showed that using plasma oxysterol screening for diagnosis of NP-C disease among ID patients is a dominant strategy.”
> “The average amount of cost saving was $3642 CAD and the incremental QALYs per each individual ID patient in oxysterol screening arm versus current practice of diagnosis NP-C was 0.0022 QALYs.”

Source: [van Karnebeek et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25095726/)

<a id="topic-2.2.1.8.4-4"></a>

###### Gene panel cost and test selection in the Australian standard of care

> “Multigene panels are becoming more accessible and cost‐effective.”
> “When gene panel tests are used, they should be symptom‐specific and must include the NPC1 and NPC2 genes.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.8.4-5"></a>

###### Manufacturer-sponsored exome testing at no charge in the United States

> “Through the program, GeneDx is slated to offer testing to U.S.-based clinicians caring for patients with known or suspected NPC who meet eligibility criteria.”
> “Patients will then be eligible to receive GeneDx's ExomeDx test at no charge and results will be provided to clinicians and their patients in as little as three weeks.”
> “Zevra Therapeutics will provide financial support for the program as part of its commitment to advancing diagnosis and care in NPC.”

Source: [GeneDx Zevra NPC sponsored genetic testing program press release (2026)](https://www.businesswire.com/news/home/20260310450068/en)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Miglustat

<a id="topic-2.2.2.1.1-1"></a>

###### Guideline recommendation: miglustat for all patients with a confirmed diagnosis

> “Miglustat, a substrate reduction therapy, is licensed as a disease‐modifying medicine to treat the neurological manifestations of patients with NPC disease.”
> “In some patients, miglustat has been shown to attenuate disease progression and improve survival.”
> “Statement #15: All patients with a confirmed diagnosis of NPC should be considered for miglustat therapy.”
> “Strength of recommendation: 1”
> “Level of evidence: B”
> “Expert's opinion: completely agree (44.83%), mostly agree (44.83%), partially agree (10.34%), partially disagree (0.00%), mostly disagree (0.00%), and completely disagree (0.00%).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.1-2"></a>

###### Candidates for miglustat and exclusions in GeneReviews

> “Thus, in countries where it is an approved therapy, individuals with a confirmed diagnosis of NPC should be considered for miglustat therapy, except individuals with NPC who:”
> “Have advanced neurologic disease / dementia;”
> “Have another life-threatening illness and an estimated life span <1 year;”
> “Have only spleen/liver enlargement.”
> “Note: Miglustat may produce loose stools and excessive flatus; these effects may be managed with dietary modification (by reduction or removal of lactose and other sugars).”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.1-3"></a>

###### Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States

> “Miglustat is approved as treatment for neurological manifestations of NPC in Europe, Japan, and Canada.”
> “It works as a substrate reduction treatment to reduce accumulation of glycosphingolipid in the lysosome.”
> “Miglustat has United States (US) approval for some forms of Gaucher disease in adults (100 mg formulation) and in certain patients with Pompe disease (65 mg formulation).”
> “It is considered off-label in the US for NPC.”
> “The FDA has stated miglustat is considered standard of care in adult and pediatric patients with NPC by experts.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

> “Miglustat, an inhibitor of glucosylceramide synthase, has been approved to treat NPC in other countries; however, its use remains off-label in the United States.”
> “Miglustat has been shown to ameliorate neurological symptoms and extend survival but does not arrest disease progression.”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

> “Targeted therapies: Treatment for the neurologic manifestations of NPC can include miglustat (approved in several countries but not currently FDA approved for standalone treatment of NPC), arimoclomol (approved for use in combination with miglustat), and levacetylleucine (standalone treatment approved by FDA).”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.1-4"></a>

###### Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort

> “Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis.”
> “Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months.”
> “12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area.”
> “The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression.”
> “At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028).”
> “Children showed an improvement in HSEM velocity of similar size at 12 months.”
> “Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years.”
> “The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.”

Source: [Patterson et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17689147/)

<a id="topic-2.2.2.1.1-5"></a>

###### Open-label extension in adult and juvenile participants

> “All patients completing the randomized trial were allowed to continue treatment in a 12-month, non-controlled open-label extension.”
> “Mean horizontal saccadic eye movement velocity (HSEM-alpha) indicated improvement in the 12-month miglustat group, and stabilization in the 24-month group; swallowing was improved or stable in 86% and in up to 93%, respectively.”
> “Ambulation was stabilized in both the 12- and 24-month groups.”
> “In an exploratory disease stability analysis of prospective data on key parameters of disease progression (HSEM-alpha, swallowing, ambulation and cognition), 13/19 (68%) patients receiving >or= 12 months' miglustat therapy had stable disease.”
> “Among all patients receiving >or= 1 dose of miglustat (n=28), the most frequent adverse events were diarrhoea, weight decrease, flatulence and tremor.”

Source: [Wraith et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20045366/)

<a id="topic-2.2.2.1.1-6"></a>

###### Open-label extension in children aged 4 to 12 years

> “Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase.”
> “Ten children completed 24 months' treatment.”
> “Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months.”
> “Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%).”

Source: [Patterson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/19822772/)

<a id="topic-2.2.2.1.1-7"></a>

###### International NPC Registry: disability during continuous miglustat therapy by age at neurological onset

> “In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between September 2009 and October 2013; 92 patients received continuous miglustat therapy.”
> “Among 84 evaluable patients, 9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years) and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations.”
> “Progression of composite disability scores appeared highest among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset.”
> “Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable patients increased with age at neurological onset.”

Source: [Patterson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4462071/)

<a id="topic-2.2.2.1.1-8"></a>

###### Survival with and without miglustat: pooled national cohorts and the NPC Registry

> “Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat.”
> “Miglustat treatment was associated with a significant reduction in the risk of mortality in neurological onset group patients (adjusted HR [95% CI] 0.510 [0.335, 0.777]; P < .01) (Figure 1A).”
> “The effect was consistent across all four age‐at‐neurological‐onset sub‐groups, with a trend that favoured miglustat treatment; all HRs were between 0.364 (late infantile patients) and 0.671 (early infantile patients).”
> “Results were statistically significant for late infantile patients (HR [95% CI] 0.364 [0.165, 0.801]; P < .05); statistical significance was not achieved in the remaining age‐at‐neurological‐onset sub‐groups (Figure 1A).”
> “Miglustat treatment was associated with a significant reduction in the risk of mortality in diagnosis group patients (HR [95% CI] 0.441 [0.293, 0.664]; P < .001) (Figure 2A).”
> “In conclusion, this study is the first exploratory analysis conducted in the largest pool of observational data for patients with NP‐C to date, treated in a real‐world setting and with a broad geographical representation.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.2.1.1-9"></a>

###### Swallowing outcomes in a single-center cohort with neurological onset before age 15 years

> “Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression.”
> “In this cohort study of 50 individuals with Niemann-Pick disease, type C1 with neurologic disease onset before age 15 years, miglustat use was associated with stabilized swallowing function and reduced aspiration risk.”
> “Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001).”
> “Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).”

Source: [Solomon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489403/)

<a id="topic-2.2.2.1.1-10"></a>

###### Infantile onset: French pediatric cohort treated in clinical practice

> “Twenty children were enrolled; 19 had NPC1 gene mutations and 1 had NPC2 gene mutations.”
> “Eight NPC1 patients had the early-infantile, eight had the late-infantile, and three had the juvenile-onset forms of NP-C.”
> “NP-C disability scale scores indicated either stabilization or improvement of neurological manifestations in 1/8, 6/8, and 1/3 NPC1 patients in these subgroups, respectively.”
> “Mild-to-moderate gastrointestinal disturbances were frequent during the first 3 months of miglustat therapy, but were easily managed with dietary modifications and/or anti-propulsive medication.”
> “Among early-infantile onset patients, a shorter delay between neurological disease onset and miglustat initiation was associated with an initial better therapeutic outcome in one patient, but miglustat did not seem to modify overall disease course in this subgroup.”

Source: [Héron et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3465012/)

<a id="topic-2.2.2.1.1-11"></a>

###### Early infantile onset: French retrospective comparison of treated and untreated patients

> “Ten patients were included in the treated group (year of birth: 2006–2012), and 16 patients in the untreated group [born 1987–2005 (n = 15), 2012 (n = 1)].”
> “Miglustat therapy was started at a median age of 24.5 months (9–29) and median duration was 30 months (11–56).”
> “Gastrointestinal adverse events were reported in 7/10 patients on miglustat.”
> “All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy.”
> “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C.”

Source: [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)

> “Evidence for miglustat efficacy in pre/perinatal and early infantile cases remains limited”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Levacetylleucine

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline recommendation: levacetylleucine for patients with neurological symptoms

> “Levacetylleucine (also known as L‐acetylleucine) is a modified amino acid derivative of leucine, approved by the FDA for treating neurological manifestations of NPC in both adult and pediatric patients.”
> “Statement #16: All patients with a confirmed diagnosis of NPC and neurological symptoms should be considered for levacetylleucine therapy.”
> “Strength of recommendation: 2”
> “Expert's opinion: completely agree (41.38%), mostly agree (37.93%), partially agree (17.24%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.2-2"></a>

###### Product history: first FDA approval for Niemann-Pick disease type C in 2024

> “Today, the U.S. Food and Drug Administration approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kilograms.”
> “The FDA granted Aqneursa Priority Review, Fast Track, Orphan Drug and Rare Pediatric Disease designations for this application.”

Source: [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c)

| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
| --- | --- | --- | --- | --- |
| “09/24/2024” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |

Source: [Drugs@FDA NDA 219132](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219132)

> “Please refer to your new drug application (NDA), dated and received January 24, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for Aqneursa (levacetylleucine) for oral suspension.”

Source: [FDA NDA approval letter (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/219132Orig1s000ltr.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Regulatory status outside the United States: European Union authorisation for Niemann-Pick disease type C

> “Aqneursa received a marketing authorisation valid throughout the EU on 19 January 2026.”
> “Aqneursa is a medicine used to treat neurological symptoms (symptoms affecting the brain and nerves) of Niemann-Pick type C (NPC) disease in adults and children aged 6 years and older who weigh at least 20 kg.”

Source: [European Medicines Agency Aqneursa EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/aqneursa)

| Field | Quoted record |
| --- | --- |
| EMA product number | “EMEA/H/C/006327” |
| Marketing authorisation holder | “Intrabio Ireland Limited” |
| Opinion adopted | “13/11/2025” |
| Marketing authorisation issued | “19/01/2026” |

Source: [European Medicines Agency Aqneursa EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/aqneursa)

<a id="topic-2.2.2.1.2-4"></a>

###### Change of ownership of the manufacturer in October 2026

> “Japan's Shionogi stepped in to purchase IntraBio and its medicine in October.”

Source: [Fierce Pharma LEMBAZ approval report (2026)](https://www.fiercepharma.com/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease)

<a id="topic-2.2.2.1.2-5"></a>

###### Molecular target: prescribing information

> “The distinct molecular target for levacetylleucine in the treatment of NPC or A-T is unknown.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### Phase 2 open-label, rater-blinded trial in participants aged 6 years or older

> “In this multi-national, open-label, rater-blinded Phase II study, patients were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥ 13 years, weight-tiered doses for patients 6–12 years), and a 6-week post-treatment washout period.”
> “33 subjects aged 7–64 years with a confirmed diagnosis of NPC were enrolled.”
> “NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% CI 0.25, 1.75, p = 0.029), as well as secondary endpoints.”
> “No treatment-related serious adverse events occurred.”

Source: [Bremova-Ertl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8361244/)

<a id="topic-2.2.2.1.2-7"></a>

###### Phase 3 crossover trial: design and population in the prescribing information

> “The safety and efficacy of AQNEURSA for the treatment of NPC were evaluated in a randomized, double-blind, placebo-controlled, two-period crossover study that evaluated the efficacy of AQNEURSA in 60 patients (Trial 1; NCT05163288).”
> “To be eligible for the study, patients had to be aged 4 years or older with a confirmed diagnosis of NPC.”
> “AQNEURSA and placebo were administered orally with or without food for 12 weeks in each period.”
> “The median age at treatment initiation was 25 years (range: 5 to 67 years).”
> “The majority of the patients (n=51, 85%) received miglustat treatment prior to randomization and during the trial.”
> “The estimated mean fSARA total score was 5.1 when patients were treated with AQNEURSA and 5.6 when patients were treated with placebo.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.2.2.1.2-8"></a>

###### SARA and fSARA treatment differences in the Niemann-Pick disease type C trial of levacetylleucine

> “The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status).”
> “The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001).”

Source: [Bremova-Ertl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38294974/)

> “The estimated treatment difference for the fSARA total score was -0.4 (95% CI: -0.7, -0.2) (Table 4).”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.2.2.1.2-9"></a>

###### Plain language summary of the phase 3 result in a state Medicaid drug evaluation

> “After 12 weeks, people taking levacetylleucine had a small improvement in some symptoms compared to people who took a placebo.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.2-10"></a>

###### Open-label extension at 12 and 18 months compared with a historical cohort

> “Fifty-three patients aged 5–67 years (45.3% female, 54.7% male) were enrolled in the EP.”
> “The mean (±SD) baseline (visit 2) score on the 5-domain NPC-CSS was 11.10 (±4.73).”
> “After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI −3.05 to −0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression.”
> “After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI −4.06 to −0.35; p = 0.023).”
> “Subgroup analysis of pediatric vs adult patients demonstrated consistent benefit with NALL.”
> “No TEAEs occurred in more than 10% of patients on NALL, and no patients had TEAEs that were assessed by the investigator as related to NALL.”

Source: [Patterson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296777/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Arimoclomol

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline recommendation: arimoclomol for patients with neurological symptoms on background miglustat

> “Arimoclomol is a small‐molecule drug classified as a heat shock protein co‐inducer, targeting HSP70, approved by the FDA in combination with miglustat for the treatment of NPC”
> “Statement #17: All patients with a confirmed diagnosis of NPC and neurological symptoms using background miglustat treatment should be considered for arimoclomol therapy.”
> “Expert's opinion: completely agree (37.93%), mostly agree (37.93%), partially agree (20.69%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.3-2"></a>

###### U.S. regulatory history: complete response letter in June 2021

> “Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC).”
> “The FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale (NPCCSS) and, in particular, the swallow domain.”
> “Further, the FDA noted in the CRL that additional data are needed to bolster confirmatory evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA.”

Source: [Orphazyme complete response letter announcement (2021)](https://www.sec.gov/Archives/edgar/data/1764791/000156459021033445/orph-ex991_6.htm)

<a id="topic-2.2.2.1.3-3"></a>

###### U.S. regulatory history: advisory committee vote in August 2024

> “CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C (NPC).”
> “The FDA has accepted the resubmission of the NDA for arimoclomol and has set a user fee goal action date (PDUFA date) of September 21, 2024.”

Source: [Zevra Therapeutics advisory committee release (2024)](https://www.biospace.com/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c)

<a id="topic-2.2.2.1.3-4"></a>

###### U.S. approval in September 2024 in combination with miglustat

> “Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).”
> “Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with NPC in adults and children 2 years of age and older.”
> “Miplyffa is the first drug approved by the FDA to treat NPC.”
> “The FDA granted Miplyffa priority review, orphan drug, rare pediatric disease, fast track and breakthrough therapy designations for this application.”

Source: [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c)

> “MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC).”
> “Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes.”

Source: [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)

<a id="topic-2.2.2.1.3-5"></a>

###### Phase 2/3 trial NPC-002: prespecified 5-domain NPCCSS primary endpoint

> “In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use.”
> “The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months.”
> “Fifty patients enrolled; 42 completed.”
> “At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo.”
> “A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression.”
> “In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006).”
> “Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo.”
> “Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%).”
> “Treatment‐related serious adverse events (n = 2) included urticaria and angioedema.”

Source: [Mengel et al. (2021a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9293014/)

<a id="topic-2.2.2.1.3-6"></a>

###### Phase 2/3 trial NPC-002: rescored 4-domain NPCCSS introduced post hoc

> “To more accurately assess changes in disease course over a 12-month time period in a heterogeneous group of patients, the Cognition domain was removed from the 5DNPCCSS and the Swallow domain was rescored to reflect linearity in disease progression.”
> “The NPC-002 post-hoc primary analysis showed a mean standard error (SE) change in R4DNPCCSS score of 0.35 (0.40) with arimoclomol (N = 34) versus 2.05 (0.54) with placebo (N = 16), and a treatment effect in favor of arimoclomol over placebo of −1.70 (p = 0.0155).”
> “In the miglustat subgroup analysis, mean (SE) change in R4DNPCCSS score was −0.23 (1.02) with arimoclomol (N = 22) versus 1.92 (3.37) with placebo (N = 12), representing a treatment effect of −2.21 (p = 0.0077).”

Source: [Mengel et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12166820/)

<a id="topic-2.2.2.1.3-7"></a>

###### Phase 2/3 trial NPC-002: results in the miglustat subgroup in the prescribing information

> “Safety and effectiveness of MIPLYFFA were assessed in Trial 1, a randomized, double-blind, placebo-controlled, 12-month trial in patients 2 to 19 years of age who had a molecularly confirmed diagnosis of NPC (NCT02612129).”
> “The randomization was stratified by miglustat use status at baseline.”
> “In Trial 1, 76% and 81% of patients in the MIPLYFFA and placebo groups, respectively, received miglustat six months or longer prior to the time of enrollment.”
> “Table 3 displays the change from baseline in R4DNPCCSS score at month 12 in patients 2 to 19 years of age with NPC who also received miglustat in Trial 1.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

| R4DNPCCSS score | MIPLYFFA with miglustat (N=26 at baseline, N=22 at month 12) | Placebo with miglustat (N=13 at baseline, N=12 at month 12) |
| --- | --- | --- |
| Baseline, mean (SD) | “8.9 (6.1)” | “7 (5.8)” |
| Change from baseline to month 12, mean (SD) | “-0.2 (1)” | “1.9 (3.4)” |
| Change from baseline to month 12, LS mean (SE) | “-0.2 (0.5)” | “2 (0.7)” |
| Placebo-subtracted difference (95% CI) | “-2.2 (-3.8, -0.6)” | Not applicable |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

> “Among these 50 patients, 39 (78%) received miglustat as background treatment in the trial.”
> “Miplyffa’s efficacy was demonstrated by the rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS) score in the patients who used miglustat as their background treatment.”
> “Compared to placebo, Miplyffa resulted in a slower disease progression as measured by the R4DNPCCSS score.”

Source: [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c)

<a id="topic-2.2.2.1.3-8"></a>

###### Appraisal of the phase 2/3 trial in a state Medicaid drug evaluation

> “There is low-certainty evidence from one 12-month, double-blind, phase II/III, randomized controlled trial (RCT) of patients age 2 to 19 years (n=50) that, when combined treatment with miglustat, arimoclomol improves symptoms of NPC compared to placebo combined with miglustat.”
> “The FDA determined the subgroup without miglustat had insufficient evidence to support use of arimoclomol monotherapy for NPC.”
> “This trial had methodological concerns with the endpoint which underwent alteration by the FDA as well as concerns with the standardization of procedures across trial sites which may reduce reliability of the results.”
> “After 12 months, people taking arimoclomol with another medicine called miglustat had a small improvement in symptoms compared to people taking placebo with miglustat.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.3-9"></a>

###### Long-term data: 48-month open-label extension of NPC-002

> “Of the 50 patients who started the DB phase, 41 entered the OLE phase, with 29 completing 48 months.”
> “During the OLE, mean (SD) 5DNPCCS and R4DNPCCSS scores increased by 3.2 (4.8) and 2.7 (4.2) over 48 months, respectively.”
> “Among patients switching from placebo to arimoclomol after the DB phase, mean annual change in 5DNPCCSS decreased from 2.0 (on placebo) to 0.1 in the first year of receiving arimoclomol and mean annual change in R4DNPCCSS decreased from 1.9 to 0.2, indicating slowing of disease progression.”
> “The score pattern in the subset of patients who received miglustat as part of their standard care regime in addition to arimoclomol (N = 33) was similar to that seen in the total population.”
> “Arimoclomol was well-tolerated over 48 months, with no new safety concerns identified.”

Source: [Mengel et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40663813/)

<a id="topic-2.2.2.1.3-10"></a>

###### Long-term data: U.S. early access program over 4 years

> “Participants were enrolled at 14 US sites.”
> “Among 109 participants, 53 (48.6%) were adults (≥18 years) and 71 (65.1%) received miglustat alongside arimoclomol.”
> “Mean (SD) arimoclomol exposure was 820 (539) days.”
> “Of 248 reported AEs, 17 events in 13 participants (12.8%) were treatment related.”
> “5DNPCCSS scores remained relatively stable throughout the program, with mean (SD) total scores of 11.0 (6.15) at Baseline (n = 100) and 12.0 (7.32) at Year 4 (n = 22).”

Source: [Berry-Kravis et al. (2026d)](https://pubmed.ncbi.nlm.nih.gov/42551329/)

<a id="topic-2.2.2.1.3-11"></a>

###### Infants younger than 24 months: open-label pediatric substudy

> “The dosing regimen used for patients <24 months differed from the regimen recommended in the FDA label.”
> “Five patients (three females, two males; aged 14–23 months at screening) were enrolled; four remained in the study >12 months; arimoclomol exposure ranged from 72 to 1109 days.”
> “All patients received concomitant miglustat.”
> “Two AEs in one patient (elevated alanine/aspartate aminotransferases) were considered probably related to arimoclomol and resolved within 51 days; the patient was withdrawn from the substudy.”
> “Further investigation in larger cohorts is warranted to elucidate the impact of arimoclomol in NPC patients under 2 years of age.”

Source: [Mengel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310637/)

<a id="topic-2.2.2.1.3-12"></a>

###### Planned supplemental application for infants younger than 24 months

> “Following the publication of its pediatric data in Molecular Genetics and Metabolism Reports, Zevra met with the U.S. Food and Drug Administration (FDA) to discuss a potential supplemental New Drug Application (sNDA) for MIPLYFFA in infants less than 24 months of age.”
> “Company anticipates filing sNDA in Q1 2027.”

Source: [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)

<a id="topic-2.2.2.1.3-13"></a>

###### Regulatory status outside the United States: refusal of European Union marketing authorisation confirmed in November 2026

> “After re-examining its initial opinion, the European Medicines Agency has confirmed its recommendation to refuse marketing authorisation for the medicine Meplyffa.”
> “The Agency issued its opinion after re-examination on 12 November 2026.”
> “The Agency had issued its initial opinion on 23 July 2026.”
> “Note: A previous application for this medicine (under the name Miplyffa) was withdrawn in March 2022.”

Source: [European Medicines Agency Meplyffa refusal (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/meplyffa)

> “At the time of the initial evaluation, there were concerns about how the data had been handled and the results analysed, which led to uncertainties about the reliability and robustness of the results.”
> “Moreover, no benefit was seen in terms of ambulation and cognition.”
> “Although data for the subgroup of patients who were also taking miglustat showed a treatment effect favouring Meplyffa, this finding was not considered robust since effectiveness had not been demonstrated in the overall population.”
> “While recognising the unmet medical need in Niemann-Pick disease type C, the Agency considered that its concerns were not resolved after re-examination and therefore confirmed the initial refusal.”

Source: [European Medicines Agency Meplyffa refusal questions and answers (2026)](https://www.ema.europa.eu/en/documents/smop-initial/questions-answer-refusal-marketing-authorisation-meplyffa-arimoclomol_en.pdf)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Other Cyclodextrin Products

<a id="topic-2.2.2.1.4-1"></a>

###### Guideline status of intrathecal and intravenous 2-hydroxypropyl-beta-cyclodextrin before the LEMBAZ approval

> “Clinical trials or expanded access programs are ongoing to evaluate the safety and efficacy of intrathecal or intravenous formulations of 2‐hydroxypropyl‐β‐cyclodextrin”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.4-2"></a>

###### HPβCD products differ in composition: VTS-270 and Trappsol Cyclo

> “VTS-270 (Kleptose HPB) and Trappsol® Cyclo™ are HPβCD products under investigation as novel treatments for NPC1.”
> “Notably, HPβCD formulations are not comprised of a single molecular species, but instead are complex mixtures of species with differing degrees of hydroxypropylation of the cyclodextrin ring.”
> “Based on the analytical differences observed between VTS-270 and Trappsol Cyclo with respect to the degree of substitution, the composition and fingerprint of the complex mixture, and the impurity profiles, these products cannot be considered to be the same; the potential biological and clinical implications of these differences are not presently known.”

Source: [Yergey et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393605/)

<a id="topic-2.2.2.1.4-3"></a>

###### Intravenous HPβCD (Trappsol Cyclo, remibetadex): sponsor and development status

> “Our lead candidate is Trappsol® Cyclo™ (remibetadex), an investigational therapy for the potential treatment of Niemann-Pick Disease Type C (“NPC”), a rare, fatal and progressive genetic disorder.”
> “Trappsol® Cyclo is administered intravenously every two weeks.”
> “The company positions Trappsol® Cyclo as a potential foundational therapy designed to be suitable for a broad patient population, including early-stage and pediatric patients.”

Source: [Rafael Holdings Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm)

<a id="topic-2.2.2.1.4-4"></a>

###### Remibetadex NDA submitted October 2026 for neurovisceral manifestations from birth

> “On October 28, 2026, Cyclo submitted a New Drug Application (“NDA”) to FDA seeking approval of Trappsol® Cyclo™ for the treatment of the neurovisceral manifestations of NPC in adult and pediatric patients from birth.”
> “The NDA includes a request for a rare pediatric disease priority review voucher.”
> “The TransportNPC™ Phase 3 trial did not meet its primary endpoint in the overall study population, and the NDA relies in part on a prespecified analysis of patients receiving background miglustat and/or leucine therapy and on a separate overall survival analysis that compared treated patients with external, non-randomized registry controls.”
> “Even if FDA approves Trappsol® Cyclo™, it may limit the indication to patients receiving background therapy, which consists of products marketed by other companies, or impose other labeling restrictions that limit market acceptance.”

Source: [Rafael Holdings Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm)

<a id="topic-2.2.2.1.4-5"></a>

###### Remibetadex regulatory timeline and anticipated FDA action

> “NDA submitted October 2026 with priority review requested; potential FDA action ~mid - 2027 if FDA files the NDA and grants priority review”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="topic-2.2.2.1.4-6"></a>

###### TransportNPC phase 3 trial of intravenous Trappsol Cyclo: design

> “The global, double-blind, placebo-controlled Phase 3 TransportNPC™ study (CTD-TCNPC-301) enrolled 94 patients with NPC, ranging in age from 3 to 70 years.”
> “Patients were randomized to receive 2000 mg/kg of Trappsol® Cyclo™ administered intravenously every two weeks (n=63) or placebo (n=31) for a 96-week period to assess change in 4DNPCSS.”

Source: [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)

> “An open-label sub-study in countries following European Medicines Agency (EMA) guidance will enroll asymptomatic or symptomatic patients from infancy up to age 3 to evaluate safety in that population.”

Source: [ClinicalTrials.gov NCT04860960](https://clinicaltrials.gov/study/NCT04860960)

<a id="topic-2.2.2.1.4-7"></a>

###### TransportNPC primary endpoint at week 96: not statistically significant

> “Primary endpoint: Trappsol® Cyclo™ demonstrated a directionally favorable treatment effect compared with placebo, indicating slowing of disease progression by 64% on change in 4DNPCSS at Week 96 (LS mean change from baseline of 0.46 vs 1.28 points; difference −0.81 points [95% CI −2.04, 0.41]; p=0.19), the result did not achieve statistical significance.”

Source: [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)

<a id="topic-2.2.2.1.4-8"></a>

###### TransportNPC safety over 96 weeks, including hearing-related adverse events

> “Serious TEAEs occurred more frequently with Trappsol® Cyclo™,35.9%, than with placebo 16.7%; however, serious TEAEs considered related to treatment were reported at similar rates 3.1% vs 3.3%.”
> “Hearing-related TEAEs were reported by 15.6% of participants receiving Trappsol® Cyclo™ and 13.3% receiving placebo, and most were mild or moderate in severity.”
> “One treatment-related event of bilateral deafness in the Trappsol® Cyclo™ group was severe.”

Source: [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)

<a id="topic-2.2.2.1.4-9"></a>

###### Company-presented infantile-onset survival analysis of Trappsol Cyclo with registry external controls

> “INPDR comparison: Treatment with Trappsol® Cyclo™ (n=41) was associated with an 85% reduction in the risk of mortality compared with matched INPDR controls (n=93), HR=0.154; 95% CI: 0.025-0.950; p=0.044.”
> “The topline data, complete dataset and overall survival analysis remain subject to full analysis and FDA regulatory review.”

Source: [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)

<a id="topic-2.2.2.1.4-10"></a>

###### TransportNPC open-label pediatric sub-study in children under 3 years

> “Newborn to <3 years (N=10): no treatment - related SAEs; 86% stable or improved on CGI - S at Week 96”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="topic-2.2.2.1.4-11"></a>

###### Phase 1/2 trial of intravenous Trappsol Cyclo: design and outcomes at 48 weeks

> “Twelve patients aged at least 2 years (2–39 years of age) with a confirmed diagnosis of NPC1 were randomized to receive one of three IV doses of HP-β-CD (1500 mg/kg, 2000 mg/kg, or 2500 mg/kg) every 2 weeks for 48 weeks.”
> “All patients received HP-β-CD; there was no placebo or other control.”
> “Of the 9 patients who completed the study, 7 were viewed by their treating physicians as having improved to some degree at the end of the study, and 2 remained stable; both outcomes are highly relevant in a progressive neurodegenerative disease.”

Source: [Sharma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10475848/)

<a id="topic-2.2.2.1.4-12"></a>

###### Australian standard of care: Trappsol Cyclo as the most advanced investigational cyclodextrin

> “Of these, the cyclodextrin Trappsol Cyclo (Cyclo Therapeutics Inc., USA) is the most advanced.”
> “Further research is needed to determine the optimal role of these novel therapies in the clinical setting.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.4-13"></a>

###### Expanded access with intravenous HPβCD in the United States and Brazil

> “HPβCD has been administered to NPC patients with approved INDs globally since 2009.”
> “Here we present safety, tolerability and efficacy data from 12 patients treated intravenously (IV) for over 7 years with HPβCD in the US and Brazil.”
> “Several patients transitioned to an alternate HPβCD.”
> “Severely affected patients demonstrated periods of stability but eventually showed progression of disease.”

Source: [Hastings et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6805667/)

<a id="topic-2.2.2.1.4-14"></a>

###### Compassionate use of intrathecal and intracerebroventricular HPβCD in Japan

> “Herein, we describe the effects of intrathecal HPB-CD in an eight-year-old patient with a perinatal onset of NPC, administered initially at a dose of 10 mg/kg every other week and increased up to 10 mg/kg twice a week.”
> “Two months later, no adverse effects were observed, thus we implanted an Ommaya reservoir to administer 20 mg/kg HPB-CD weekly thereafter (Table 1).”

Source: [Matsuo et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5121362/)

> “To demonstrate long-term efficacy and safety of intrathecal HPBCD (IT-HPBCD) treatment for NPC, we herein reports five patients with NPC treated using IT-HPBCD for 4-11 years.”
> “Mild-to-moderate hearing loss was observed in three patients.”
> “Long-term treatment with IT-HPBCD may suppress neurological deterioration in patients with NPC; however, the treatment outcome is dependent on the neurological status at the time of diagnosis, and disease progression is not completely inhibited.”

Source: [Matsuo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38448301/)

<a id="topic-2.2.2.1.4-15"></a>

###### Single-patient intrathecal HPβCD under an individual IND in the United States

> “The study drug was administered under an individual investigational new drug (IND) application filed with the FDA (IND 119,208).”
> “The subject received 200mg intrathecal HP-β-CD administered biweekly via lumbar puncture.”
> “The subject has developed subclinical hearing loss at high frequency that is likely HP-β-CD related.”

Source: [Maarup et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4633280/)

<a id="topic-2.2.2.1.4-16"></a>

###### Intrathecal HPβCD in a child with severe infantile-onset disease in Spain

> “The initial dose of 175 mg was gradually increased over the first 6 months to reach 325 mg.”
> “Intrathecal hydroxypropyl-β-cyclodextrin therapy is safe, but its efficacy seems questionable in a patient with the severe infantile form of Niemann-Pick disease type C.”

Source: [Roch Santed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6451626/)

<a id="topic-2.2.2.1.4-17"></a>

###### Combined intrathecal and intravenous Trappsol Cyclo in two children in Greece

> “Two preparations are commercially available: Trappsol®Cyclo™ and VTS-270.”
> “High intrathecal (900mg) and low intravenous (350–500mg/kg) doses of HP-β-CD (Trappsol®Cyclo™) were administrated twice monthly to the patients in addition to miglustat therapy.”
> “The combination therapy of miglustat and HP-β-CD resulted in disease stabilization in both patients.”

Source: [Bountouvi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8195555/)

<a id="topic-2.2.2.1.4-18"></a>

###### Systematic review assessment of HPβCD evidence

> “HPβCD demonstrated biological target engagement, including changes in cholesterol-related biomarkers, but clinical findings were mixed: uncontrolled intrathecal and intravenous studies suggested stabilization or improvement, whereas controlled evidence was less supportive.”
> “Hearing impairment remained an important safety concern.”
> “HPβCD remains investigational because its biological activity has not translated into consistent controlled clinical benefit and requires careful safety monitoring.”

Source: [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Supportive and Symptomatic Care

<a id="topic-2.2.2.1.5-1"></a>

###### Supportive care recommended with multidisciplinary specialist input

> “Supportive care to improve quality of life, maximize function, and reduce complications is recommended.”
> “This ideally involves multidisciplinary care by specialists in relevant fields”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.5-2"></a>

###### Supportive options described in a state Medicaid drug class review

> “Most other options are supportive in nature such as mobility aids and rehabilitation for strength and balance, or medications to treat symptoms such as spasticity, hypersalivation, epilepsy, and cataplexy.”
> “Epilepsy should be treated by a specialist as some medications, including carbamazepine and vigabatrin, may aggravate the disease.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Neurological symptoms: spasticity, cataplexy, and seizures

> “Spasticity and spasms should be treated initially by non‐pharmacological means.”
> “If these are unsuccessful, pharmacological agents, including baclofen, tizanidine, benzodiazepines, dantrolene sodium, and botulinum toxin injections, may be considered.”
> “Protriptyline, other tricyclic agents, methylphenidate or modafinil may be efficacious for cataplexy.”
> “Seizures should be treated by a neurologist aware of the disease, considering the possibility of aggravation with some anti‐seizure drugs like carbamazepine and vigabatrin.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.5-4"></a>

###### Swallowing and nutrition: dietary modification and gastrostomy

> “Dietary modification and compensatory postures may be beneficial for individuals with dysphagia.”
> “Counseling individuals on the long‐term utility of assisted feeding by gastrostomy tube is recommended early in the disease to prevent delay and improve quality of life.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.5-5"></a>

###### Hypersalivation and drooling

> “Patients should be treated with established interventions, including postural drainage ±pharmacological agents such as hyoscine hydrobromide transdermal patches; glycopyrronium bromide orally, subcutaneously or via a gastrostomy and small doses of orally administered atropine, or parotid/submandibular glandular injections of botulinum toxin.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.5-6"></a>

###### Hearing impairment: hearing devices

> “When appropriate, patients should be offered hearing devices to improve general communication.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

> “Use of amplification should be guided by clinical needs & recommendations of treating audiologist.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.1.5-7"></a>

###### Mobility, movement disorders, and sleep

> “Strategies to maintain optimal mobility and reduce falls, such as providing walking/mobility aids, ankle‐foot orthotics, and exercise programs, should be sought proactively to prolong mobility and transfer ability.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

> “A nocturnal sedative may be indicated; melatonin is often effective & well tolerated.”
> “Psychiatric manifestations may be resistant to standard drug therapies.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Transplantation and Investigational Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Investigational agents and modalities named in the 2025 guideline

> “Other experimental therapies include the orally administered agents efavirenz, a non‐nucleoside reverse transcriptase antiretroviral inhibitor, and nizubaglustat, a selective dual inhibitor of ceramide glucosyltransferase and non‐lysosomal neutral glucosylceramidase (NLGase)”
> “In addition, several other therapeutic modalities, including gene therapy, antisense oligonucleotide (ASO) therapy for patients with specific targetable mutations, and CRISPR/Cas9 technology in animal studies, are underway with positive preliminary findings”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.6-2"></a>

###### Gene and cell-based therapies remain preclinical

> “Gene therapy and cell‐based therapies (mesenchymal stem cells) have gained much interest in the pre‐clinical setting,”
> “but there have been no clinical trials to our knowledge to date.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.6-3"></a>

###### Nizubaglustat phase 3 trial in late-infantile and juvenile forms

> “An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis”

Source: [ClinicalTrials.gov NCT07054515](https://clinicaltrials.gov/study/NCT07054515)

<a id="topic-2.2.2.1.6-4"></a>

###### Efavirenz phase 2 trial in adult and late juvenile-onset disease

> “This is a single-center, phase II clinical trial to evaluate the efficacy and safety of Efavirenz in addition to standard of care in patients diagnosed with adult or late juvenile-onset NPC with cognitive impairment.”
> “All enrolled patients will be treated orally with 25 mg/d of Efavirenz for 52 weeks (1 year).”

Source: [Gascón-Bayarri et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9726274/)

<a id="topic-2.2.2.1.6-5"></a>

###### Systematic review assessment of evidence for investigational agents

> “Evidence for vorinostat, NAC, efavirenz, and nizubaglustat was limited by small samples and early-phase or uncontrolled designs.”

Source: [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/)

<a id="topic-2.2.2.1.6-6"></a>

###### Allogeneic bone marrow transplantation in NPC2: case reports

> “In this report we describe the first successful allogeneic bone marrow transplantation for this condition in a 16-month-old boy homozygous for the NPC2 p.E20X mutation, which has hitherto been reported to cause disease with a severe phenotype.”
> “This 'graft versus substrate' reaction was managed with intensive immune suppressant therapy, and it gradually resolved as the substrate was cleared by the engrafted donor macrophages.”

Source: [Bonney et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20393800/)

> “In contrast to the previously reported patients with the same mutations, our patient has no respiratory compromise and has made some developmental progress (especially gross motor), though is significantly delayed (particularly in speech and language).”
> “Haematopoietic stem cell transplantation (HSCT) could be considered for patients with this mutation as long as performed early in the course of the disease.”

Source: [Breen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23219289/)

<a id="topic-2.2.2.1.6-7"></a>

###### Liver transplantation in children with neonatal liver failure: case series

> “Nine children were identified (six centres).”
> “Neonatal acute liver failure was the most common indication for LTx (seven children).”
> “Neurological symptoms developed in 4/7 (57%) patients at median 9 (range: 5–13) years following LTx.”
> “Neurological disease is not prevented in the majority of patients.”
> “LTx still remains controversial in NPC.”

Source: [Modin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8470073/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

- No currently available therapy for NPC is curative. Before the LEMBAZ approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death.
- Age and weight limits: FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients 2 years of age or older (arimoclomol, in combination with miglustat) or weighing 15 kg or more (levacetylleucine), leaving limited options for early infantile-onset NPC. An open-label substudy of arimoclomol in infants younger than 24 months enrolled 5 participants aged 14 to 23 months, and the company anticipates filing a supplemental application for this age group in Q1 2027.
- Miglustat: miglustat is used off-label for NPC in the United States. In a comparison of 10 treated and 16 untreated individuals with early infantile NP-C, all treated patients developed loss of psychomotor acquisitions or additional neurological symptoms, and the authors report that “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C”. In a pooled observational analysis, the hazard ratio for mortality with miglustat was 0.671 in early infantile patients, a result that did not achieve statistical significance, and 0.364 (95% CI 0.165, 0.801) in late infantile patients.
- Levacetylleucine: the randomized, placebo-controlled crossover trial enrolled 60 participants with a median age of 25 years (range 5 to 67 years) and treated each period for 12 weeks; the estimated treatment difference in the fSARA total score was -0.4 (95% CI -0.7, -0.2).
- Arimoclomol: efficacy was demonstrated in patients receiving background miglustat, with a placebo-subtracted difference in the rescored 4-domain NPCCSS of -2.2 (95% CI -3.8, -0.6) at month 12. The FDA determined that evidence for arimoclomol monotherapy was insufficient, and after re-examination on 12 November 2026 the European Medicines Agency confirmed its recommendation to refuse marketing authorisation for arimoclomol (Meplyffa).
- Evidence gaps: the arimoclomol and levacetylleucine trials did not address nonneurological manifestations such as liver disease, no published studies address coadministration of the two drugs, and data beyond 5 years are extremely limited. Differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.
- Other cyclodextrin products: in the TransportNPC phase 3 trial of intravenous Trappsol Cyclo (remibetadex), the primary endpoint at Week 96 did not achieve statistical significance (p=0.19), and hearing-related adverse events occurred in 15.6% of participants receiving Trappsol Cyclo and 13.3% receiving placebo; an NDA was submitted on October 28, 2026. One analysis concluded that HPβCD remains investigational and that hearing impairment is an important safety concern.
- Supportive care: most other options are supportive in nature, and for many individuals clinical trial participation may be the only access to disease-modifying treatment.

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf); [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c); [Mengel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310637/); [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm); [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf); [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/); [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/); [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf); [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf); [European Medicines Agency Meplyffa refusal (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/meplyffa); [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/); [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/); [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm); [Rafael Holdings Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm); [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.7-2"></a>

###### No curative therapy and restricted access to combination treatment

> “No currently available therapies for NPC are curative.”
> “Improving the accessibility and affordability of novel therapies is crucial for enhancing patient outcomes in NPC”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.7-3"></a>

###### No therapy shown to reduce mortality before the LEMBAZ approval

> “Prior to this approval action, two therapies were approved for NPC, but neither has been shown to reduce the risk of death.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.2.2.1.7-4"></a>

###### Sponsor and investigator statements on limited options in infantile-onset disease

> “There are limited therapies for patients with rapidly progressive and fatal infantile-onset NPC, none of which have demonstrated survival benefit”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

> “FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients ≥2 years of age (arimoclomol) or ≥15 kg (levacetylleucine), leaving limited treatment options for individuals with early I-NPC.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

> “No therapies have been approved by the FDA to improve survival in NPC.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.1.7-5"></a>

###### Evidence gaps for arimoclomol and levacetylleucine identified by the ACMG

> “Neither trial addressed nonneurological manifestations, such as liver disease.”
> “There are no published studies of outcomes or safety addressing coadministration of arimoclomol and levacetylleucine.”
> “Available data for treatment of NPC with arimoclomol or levacetylleucine beyond 5 years are extremely limited; long-term outcomes are not known.”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

<a id="topic-2.2.2.1.7-6"></a>

###### Evidence gaps identified in a state Medicaid drug class review

> “There is insufficient evidence of the efficacy and safety of combination therapy of arimoclomol used with levacetylleucine.”
> “There were no significant safety signals with either medication, but data is limited by small sample sizes and short study durations of placebo control.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.7-7"></a>

###### Limited access to disease-modifying therapy in the Australian standard of care

> “Disease‐modifying treatment options for NP‐C are limited (Table 5).”
> “For many individuals, clinical trial participation may be the only way to access disease‐modifying treatment.”
> “With no cure and limited access to disease‐modifying therapy, optimal management in Australia comprises symptomatic treatment of clinical manifestations and ongoing monitoring.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.7-8"></a>

###### Systematic review: therapies cannot be compared directly

> “However, differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.”

Source: [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

- Indication: LEMBAZ is indicated to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC whose neurological manifestations started at less than 6 years of age. Safety and effectiveness have not been established in pediatric patients who weigh less than 7 kg or whose neurological manifestations started at 6 years of age or older.
- Position relative to other therapies: before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. In the label's integrated survival analysis, longer overall survival was observed independent of baseline miglustat use. Published recommendations state that all patients with a confirmed diagnosis should be considered for miglustat, those with neurological symptoms for levacetylleucine, and those with neurological symptoms on background miglustat for arimoclomol; more than 75% of participants in the arimoclomol and levacetylleucine pivotal trials were taking miglustat. The company describes adrabetadex as “a foundational therapy that can be safely combined with other approved NPC treatments”, based on a safety profile generally similar with and without additional therapies.
- Anticipated use: the company states that approximately half of those living with NPC in the United States, 475 children, have infantile-onset NPC, and that early intervention can make the greatest difference.
- Care setting: LEMBAZ is administered intrathecally every two weeks over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures, with local anesthetic and sedation as indicated by the patient's clinical condition. A comprehensive audiology evaluation is performed before use. Lembaz is exclusively available through CuraScript SD by Evernorth and is billed in medical buy-and-bill settings without a product-specific HCPCS code. Published recommendations call for referral to a center with expertise in NPC wherever possible.

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/); [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/); [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/); [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf); [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)

<a id="topic-2.2.2.2-2"></a>

###### Guideline rationale for combination treatment

> “In both arimoclomol and levacetylleucine pivotal clinical trials, more than 75% of study participants were taking miglustat, highlighting the importance and safety of combination therapy”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.2-3"></a>

###### Guideline recommendation for referral to an expert center

> “Wherever possible, patients identified with NPC should be referred to a center with expertise in the care of this condition.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.2-4"></a>

###### Company-presented positioning of adrabetadex as a foundational therapy combined with other approved treatments

> “The safety profile of adrabetadex was generally similar with and without the use of additional therapies, supporting its use as a foundational therapy that can be safely combined with other approved NPC treatments.”

Source: [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)

<a id="topic-2.2.2.2-5"></a>

###### Intended use: early intervention in infantile-onset disease

> “For the first time, LEMBAZ gives clinicians a way to address the underlying cholesterol trafficking defect that causes infantile-onset NPC, where early intervention can make the greatest difference.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.2.2-6"></a>

###### Care setting: administration sites and treatment center preparation

> “Proximity to an administration site should never stand between a family and treatment.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

> “Help treatment centers establish the necessary workflows to care for individuals who may receive adrabetadex”

Source: [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)

<a id="topic-2.2.2.2-7"></a>

###### Emerging NPC treatment paradigm described by a competing cyclodextrin sponsor

> “NPC treatment landscape evolving from no approved therapy to combination regimens”
> “Remibetadex has been designed to have a distinct mechanism of action that removes accumulated cholesterol independent of abnormal NPC protein, complementary to existing therapies”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Company-presented survival by onset category and baseline miglustat use

> “The OS benefit was seen in participants treated with miglustat and not treated with miglustat at baseline”
> “Survival benefit was consistent for early and late I-NPC, as well as for comparisons to each individual external control cohort”

Source: [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)

<a id="topic-2.2.2.3-2"></a>

###### Company-presented survival by baseline disease burden in infantile-onset disease

> “No deaths were observed among 29 adrabetadex-treated participants with minimal baseline disease burden (R4DNPCCSS <4) during up to 11.3 years of treatment, consistent with earlier intervention before irreversible neurodegeneration.”
> “The median KM-estimated overall survival was numerically higher for adrabetadex-treated participants than for the untreated cohort in all the quartiles; in the severe quartile, the 5-year KM-estimated survival was 50% compared to 17%.”
> “Some caution is warranted when interpreting results between the two cohorts, considering the variations in group size, as well as the absence of a matching procedure between the two cohorts.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.3-3"></a>

###### Company-presented disease progression by time from neurological onset to treatment

> “A total of 25 participants were included (prompt treatment: n=9; delayed treatment: n=16) (Table 1).”
> “Median (Q1, Q3) baseline R4DNPCCSS score was lower in the prompt treatment group vs the delayed treatment group: 1.5 (0.50, 2.5) vs 5.0 (2.0, 10.0).”
> “Participants who initiated adrabetadex within 1 year of neurological symptom onset demonstrated numerically lower R4DNPCCSS progression from baseline scores compared with later treatment initiation.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.3-4"></a>

###### Neurological onset at 6 years or older: outside the approved indication

> “Our work for families whose neurological symptoms began at age 6 or later continues, and we will keep you informed along the way.”

Source: [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)

> “Review data from individuals with neurological onset at greater than 6 years of age”

Source: [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)

<a id="topic-2.2.2.3-5"></a>

###### Background miglustat or leucine use and the intravenous HPβCD treatment effect in TransportNPC

> “Prespecified analysis: Among patients receiving background miglustat and/or leucine therapy (n=78), Trappsol® Cyclo™ indicating slowing of disease progression by 71% compared with placebo at Week 96 (LS mean change from baseline of 0.46 vs 1.57 points; difference −1.11 points [95% CI −2.19, −0.02]; p=0.046).”

Source: [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)

<a id="topic-2.2.2.3-6"></a>

###### Subtype differences for the other approved therapies: state Medicaid drug class review

> “There is insufficient evidence arimoclomol with miglustat is effective for adolescent- or adult-onset NPC.”
> “It is unclear if there are differences in efficacy and safety of either drug for other subtypes of NPC based on age of onset or specific mutation.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Guideline statements on predicting treatment response by subtype

> “Additionally, predicting patient treatment responses remains challenging, further supporting the potential benefits of a combined therapeutic approach”
> “Future research priorities must focus on identifying the optimal timing for individual therapies during disease progression and understanding the most effective treatment combinations for various NPC patient subtypes.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Multidisciplinary follow-up and baseline assessment

> “Statement #14: Patients with NPC exhibit multisystem disease manifestations and benefit from holistic, multidisciplinary follow‐up from physicians and allied HCPs with experience in this condition.”
> “A baseline assessment at diagnosis is required to determine the current level of disease severity and retrospectively estimate the rate of progression”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.4-2"></a>

###### Recommended monitoring of swallowing, hearing, and cognition in the 2025 guideline

> “The presence of dysphagia, aspiration and response to therapy should be documented at diagnosis and then every 6 months in children and every 12 months in adults if the patient is asymptomatic with stable disease.”
> “Hearing assessments should be performed at the time of diagnosis and every 12 months to document the presence of hearing loss.”
> “Individuals with NPC benefit from regular evaluation of their cognitive function (at diagnosis and every 12 months), and consideration should be given to changes in their cognitive ability that may impact independence/school/work and daily living activities.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.4-3"></a>

###### Recommended surveillance schedule in GeneReviews

| Concern | Evaluation | Frequency |
| --- | --- | --- |
| Interval medical history | “Establish rate of disease progression.” | “Every 6 mos” |
| NPC clinical severity score | “Document progression & response to therapy of key disease features.” | “Every 6 mos” |
| Hearing impairment | “Audiometry for new-onset hearing loss or its progression” | “Every 12 mos” |
| Nutrition and feeding | “Document nutritional status, presence/progression of dysphagia, & aspiration risk.” | “Every 6 mos in children; in adults, frequency could be ↓ to every 12 mos if asymptomatic & disease is stable” |

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.4-4"></a>

###### Care coordination and social work support

> “Coordinate care to manage multiple subspecialty appointments, equipment, medications, & supplies.”
> “Ensure appropriate social work involvement to connect families w/local resources, respite, & support.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

> “Disease‐specific patient care is primarily conducted within the tertiary setting, with allied health, disability support services and general medical care occurring in a variety of external settings.”
> “The MDT should strive to provide individuals with NP‐C and their carers with a single treatment plan that accounts for regular assessments, examinations and medications.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.4-5"></a>

###### Proactive swallowing surveillance for silent aspiration

> “Our findings support proactive swallowing surveillance in patients with NPC1, including consideration of routine instrumental evaluations (VFSS or FEES) even in the absence of overt clinical symptoms, particularly as neurologic severity increases.”

Source: [Solomon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13539892/)

<a id="topic-2.2.2.4-6"></a>

###### Transition to adult services and palliative care planning

> “Statement #20: Most children with late infantile and juvenile onset NPC are expected to reach adulthood with complex medical and psychosocial needs.”
> “The transition from pediatric to adult services should begin early and requires appropriate services in the community to provide a seamless transition from childhood to adult life.”
> “Statement #21: Specialist center care providers, family physicians/pediatricians, and local palliative care services should develop close working links to support individuals and families with NPC throughout their lifespan.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.4-7"></a>

###### Audiology monitoring during LEMBAZ treatment described for families

> “Before you or your child starts LEMBAZ, your healthcare provider will do a complete hearing evaluation (audiology evaluation) to establish baseline hearing levels.”
> “If the dosage level stays the same for 2 doses in a row, or the maximum dose is reached, hearing evaluations will be done once a month until 3 stable results in a row are obtained.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.2.4-8"></a>

###### Peer support for families considering LEMBAZ

> “Recognizing the value of families learning from one another, Beren has also launched the Caregiver Ambassador Program to connect families considering LEMBAZ with caregivers who have firsthand experience with treatment.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### Postmarketing commitment 5103-1: leachables data for the container closure system

> “Submit the 3-month and 6-month leachables data from the ongoing stability studies for the adrabetadex drug product to verify the kinetic modeling predictions provided in the NDA and confirm the safety profile of the container closure system.”
> “The study must evaluate the drug product stored in the inverted orientation at both long-term (25°C/60% RH) and accelerated (40°C/75% RH) storage conditions.”
> “Any leachable observed at levels exceeding the Safety Concern Threshold (SCT) of 0.15 μg/day should be confidently identified, and a toxicological risk assessment should be included with the subsequent leachable data submissions.”
> “The timetable you submitted on November 13, 2026, states that you will conduct this study according to the following schedule:”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

| Commitment | Study completion | Final report submission |
| --- | --- | --- |
| 5103-1 | “03/2027” | “06/2027” |

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-2"></a>

###### Pediatric Research Equity Act status

> “Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-3"></a>

###### Labeling and reporting obligations in the approval letter

> “We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).”
> “Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-4"></a>

###### Rare pediatric disease priority review voucher: marketing condition

> “FDA may revoke the PRV if the rare pediatric disease product for which the PRV was awarded is not marketed in the U.S. within 1 year following the date of approval.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### Rare pediatric disease priority review voucher: post-approval report

> “The sponsor of an approved rare pediatric disease product application who is awarded a PRV must submit a report to FDA no later than 5 years after approval that addresses, for each of the first 4 post-approval years:”
> “the estimated population in the U.S. suffering from the rare pediatric disease for which the product was approved (both the entire population and the population aged 0 through 18 years)”
> “the actual amount of product distributed in the U.S.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-2"></a>

###### Annual status reports on the postmarketing commitment

> “In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-3"></a>

###### Adverse reaction reporting

> “To report SUSPECTED ADVERSE REACTIONS, contact Mandos, LLC at 1-844-237-3600 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.2.2.6-4"></a>

###### Real-world evidence generation planned by the manufacturer

> “Financing proceeds will support a comprehensive set of programs in anticipation of a potential approval and launch of adrabetadex that best provides access and meaningful support to the NPC community, including:”
> “Generating longitudinal real-world evidence and shared learning”

Source: [Beren Therapeutics financing press release (2026)](https://www.berentx.com/news/beren-secures-300m-financing-to-support-the-potential-commercial-launch-of-adrabetadex/)

<a id="topic-2.2.2.6-5"></a>

###### Registered post-approval studies

No evidence found.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

- Treatment goals: disease-modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and extending lifespan beyond that predicted by natural history data. Treatment goals are established at diagnosis and reviewed regularly, aiming to improve or maintain physical and psychosocial wellbeing.
- Survival in the label analysis: the FDA examined the survival of 36 participants treated with Lembaz across three clinical studies and an expanded access program against a matched external control group. Deaths occurred in 12 (33.3%) LEMBAZ-treated participants and 24 (66.9%) controls; the hazard ratio for death was 0.45 (95% CI 0.21, 0.95), a 55% reduction in the risk of death, and median survival was 8.5 years with treatment and 4.9 years in controls. Longer overall survival was observed independent of baseline miglustat use.
- Survival in a separate company analysis: deaths occurred in 17 (23.6%) adrabetadex-treated participants and 44 (61.2%) external controls, with a hazard ratio of 0.289 (95% CI 0.141, 0.593; P < 0.0001), reported by the company as a 71% reduction in the risk of mortality; the 5-year survival rate was 84% with adrabetadex and 42% in external controls.
- Disease progression: in a company analysis of 79 treated participants, the annual rate of progression on the rescored 4-domain NPCCSS fell from 1.34 units/year before treatment to 0.76 units per year after treatment, a 43% reduction (P=0.0055). An observational cohort receiving routine clinical care progressed by 1.5 units/year on the 5-domain NPCCSS. The company approval announcement states: “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”. Among five individuals treated with intrathecal HPBCD for 4 to 11 years, some disease progression continued.
- Expected harm: treatment with LEMBAZ has resulted in permanent hearing impairment; 37% (22/59) of patients in Trial 3 and an expanded access program experienced hearing impairment.

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf); [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/); [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf); [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf); [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/); [Matsuo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38448301/)

<a id="topic-2.2.2.7-2"></a>

###### Guideline definition of disease-modifying therapy

> “For the purpose of this paper, disease‐modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and ultimately extending lifespan beyond that predicted by available natural history data.”
> “To understand the effects of disease‐modifying therapy in NPC, information about the natural history of disease progression is required.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.7-3"></a>

###### Guideline treatment goals and follow-up

> “Statement #19: NPC is a progressive condition, and patients require regular follow‐up to monitor disease severity, treatment response, and recurrence.”
> “Treatment goals should be established at diagnosis and reviewed regularly, aimed at improving or maintaining the physical and psychosocial wellbeing of individuals with NPC and their families.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.7-4"></a>

###### Natural history progression benchmark and company-presented progression with long-term adrabetadex

> “In an observational cohort of individuals with NPC receiving routine clinical care, an annualized progression rate of 1.5 units/year was observed on the 5-domain NPC Clinical Severity Scale (NPCCSS).”
> “Both prompt and delayed adrabetadex treatment were associated with slower disease progression relative to published natural history data.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.7-5"></a>

###### Investigator statement: lost neurological function is not regained

> “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.2.7-6"></a>

###### Stabilization as a clinically meaningful outcome in rapidly progressive infantile-onset disease

> “In rapidly progressive infantile - onset NPC, stabilization and improvement are considered clinically - meaningful outcomes indicative of clinical improvement”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="topic-2.2.2.7-7"></a>

###### Long-term intrathecal HPβCD: stabilization without complete arrest of progression

> “Furthermore, long-term treatment with IT-HPBCD may suppress neurological deterioration in patients with NPC; however, patients still experience some disease progression.”

Source: [Matsuo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38448301/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
